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Abstract 
The purpose of this dissertation was to provide an overview of acute intermittent porphyria, 
focussing on the structure and function of the enzyme, porphobilinogen deaminase (PBGD), 
as well as experimentally demonstrating the use of kinetic, structural and thermodynamic 
approaches to shed light on the enzyme reaction. The key focus was to investigate the effect 
of three mutations of the active site lysine 98 residue (K98) on the enzyme’s stability and 
mechanism. Two clinically relevant PBGD mutants, the K98E and K98R were expressed. Both 
of these mutants have previously been described in patients. We engineered and expressed 
an additional mutant, K98A, in order to investigate the effect of charge at this residue.   
The K98E, K98R and K98A recombinant proteins were successfully engineered, expressed 
and purified. These mutations were kinetically characterised, and the low enzyme activity 
supports the fact that the K98E and the K98R are known-disease causing mutations. The 
negligible activity of the K98A and K98R mutants was predicted as a result of a loss of DPM 
co-factor binding, which was analysed and proved with a co-factor spectral shift assay.  Further 
attempts to examine the interaction of co-factor binding involved removal of the bound co-
factor from wild type enzyme, in order to investigate the possible interaction of the ‘apo’-
enzyme with the DPM co-factor. However, no results were obtained to elucidate this 
interaction, largely due to the highly unstable nature of the generated ‘apo’-enzyme.   
Native polyacrylamide gel electrophoresis (PAGE) was performed in order to observe changes 
in enzyme-substrate complexes between the wild type and the different mutant proteins. The 
enzyme-substrate complexes for the wild type were clearly shown, however we could not do 
so in our mutant proteins.  
The secondary structure estimations as well as the conformational stability of the mutants were 
tested with the use of circular dichroism.  Far- and near-UV analysis provided insight into the 
effect of each mutation on the enzyme’s secondary and tertiary structure respectively. Results 
indicate that the different mutations cause marginal alterations in secondary structure, and 
resulted in changes of aromatic ring conformations in the near-UV analysis. Finally, modelling 
of each mutation to known crystal structures of the human enzyme was done in order to provide 
a rationalisation of kinetic and conformational data. Although this provided only a static image 
and estimation of the structural effect of each mutation, it did allow for some speculation in 
order to rationalise the kinetic and conformational data obtained.  Overall, this work illustrates 
how the characterisation of expressed, purified, AIP-associated mutant enzymes aids our 
understanding of the complex structure and mechanism of the PBGD enzyme.  
   1 
 
  
 
 
 
Chapter 1 
 
 
 
Literature Review and Development of Dissertation 
 
 
   2 
 
Introduction 
This chapter provides a review of the current literature. The scope of this review includes haem, 
(its formation and regulation), an overview of the porphyrias (including the classification, 
diagnosis, and need for molecular analysis) followed by a review of acute intermittent porphyria 
(AIP) focussing on the molecular basis of the disease related to PBGD structure and function. 
The study rationale as well as research question and aims for this dissertation follow at the 
end of this chapter. 
 
Haem 
Haem is central to the metabolic processes of most living organisms, including electron 
transport and enzyme catalysis [1]. In majority of species, haem cannot be obtained through 
the diet, but rather has to be produced intracellularly. Indeed haem is synthesised in every cell, 
but the largest proportion (80%) occurs in the erythropoïetic (red blood) cells and a further 
(15%) in parenchymal cells within the liver [2]. Haem also serves as a prosthetic group for 
many and various kinds of proteins, including haemoglobin, cytochrome P450s and 
peroxidases [3,4]. The structure of haem is illustrated in Figure 1.1. It is comprised of a 
protoporphyrin IX tetrapyrrole molecule, containing ferrous iron (Fe2+). 
 
 
 
Figure 1.1 The chemical structure of haem (ChEBI_26355), with the ferrous iron (Fe2+) within its 
tetrapyrrole centre. Image generated by ChemSketch, Version 2.0 for Windows [5]. Molfile of haem 
imported from Chemical Entities of Biological Interest (ChEBI) database [6]. 
 
Haem Biosynthesis 
Haem is produced via a pathway consisting of a series of enzyme-catalysed reactions [3].  
However, the pathway is slightly different amongst different species. In the first reaction in 
plants, bacteria and algae, the porphyrin precursor aminolevulinic acid (ALA), is produced from 
glutamate via the C5 pathway [6,7].  In mammals and fungi, however, the ALA is produced 
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from from glycine and succinyl coA (the citric acid cycle), by the enzyme aminolevulinic acid 
synthase (ALAS), followed by translocation into the cytosol to produce the second precursor, 
porphobilinogen (PBG) by aminolevulinic acid dehydratase (ALAD) [9,10].  PBG is then 
polymerized in a series of 4 steps by porphobilinogen deaminase (PBGD), forming 
hydroxymethylbilane (HMB), the first tetrapyrrole in the pathway.  
 
Uroporphyrinogen III synthase (UROS) then converts the HMB to urophoryrinogen III, followed 
by condensation to coprophyrinogen III by urophoryrinogen decarboxylase (UROD). 
Coprophyrinogen III is transcolated back into the mitochondria whereby coprophyrinogen III 
oxidase (CPO) catalyses an oxidative decarboxylation reaction to form protoporphyrinogen IX.  
Protoporhyrin oxidase (PPOX) allows for the oxidation of protophyrinogen IX to protoporphyrin 
IX. Finally, ferrochelatase (FC) produces haem with the insertion of the ferrous iron (Fe2+) into 
the tetrapyrrole centre  of the protoporphyrin IX molecules [11,12].   
Figure 1.2  The biosynthesis of haem as adapted from [8,13]. Enzyme for each reaction is indicated in bold.  
Molfiles were imported from Chemical Entities of Biological Interest (ChEBI) database (Image and reaction 
constructed in ChemSketch, Version 2.0 for Windows [5].   
 
Tetrapyrroles within the haem biosynthesis pathway are referred to as porphyrins, or porphyrin 
intermediates, whereas the two linear products, ALA and PBG, are known as the porphyrin 
precursors.  Under reducing conditions, the porphyrin intermediates may also be referred to 
porphyrinogens, whereas upon oxidation, they are called porphyrins [14,15].  
  
MITOCHONDRION CYTOSOL 
PPOX	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Regulation of Haem Biosynthesis 
Maintenance of the levels of haem within a cell is crucial, as an excess of haem is toxic to cells 
[16].  Therefore the pathway needs to have some form of regulation.  The formation of ALA in 
the first reaction is the rate limiting step within the haem biosynthesis pathway and the 
regulation of this reaction is controlled differently in erythroid and liver cells [17].  The ALAS 
enzyme has two isoforms, namely the ubiquitous (ALAS1) and the erythroid specific (ALAS2).  
 
In the liver, ALAS1 may be regulated by haem itself, acting as a suppressor on the synthesis 
and translocation of ALAS1 to the mitochondria, and thus leading to the formation of a negative 
feedback cycle [18].  In erythroid cells, however, ALAS2 is only induced in cases when the 
cycle is already active [19].  ALAS2 is regulated transcriptionally by erythroid-specific factors, 
as well as cellular iron concentrations [11]. The ALAS2 gene has an iron regulatory element 
(IRE) located within the 5’- of its mRNA. This allows for the inhibition of the ALAS2 translation 
when cellular iron concentrations are too low for optimum haem biosynthesis [20].  
 
The Porphyrias 
Overview 
The porphyrias are a group of metabolic inherited diseases, involving and arising from defects 
in the enzymes of the haem biosynthetic pathway [21].  As described earlier, under normal 
circumstances, the biosynthesis of haem is tightly controlled by means of a negative feedback 
cycle [3].  In the case of the porphyrias, however, genetic mutations within one or more of the 
enzymes of this pathway lead to a loss of the enzyme’s normal activity, and results in the 
potential failure to produce sufficient haem [22]. This potential failure to control the demand on 
the cycle leads to up-regulation of the pathway and to the subsequent and further build-up of 
the porphyrin precursors, ALA and PBG, as well as porphyrin intermediates (or 
porphyrinogens) further along the pathway [23].  
 
The specific pattern of haem precursor and intermediate accumulation determines the clinical 
profile with either the presence of skin lesions, acute neurovisceral attacks, or both [2].  The 
consequent build-up of the porphyrinogens results in accumulation of the oxidised porphyrin 
products and results in patients suffering from skin lesions [24]. As porphyrins are light 
sensitive molecules, exposure of the skin, in which excess porphyrins are concentrated and/or 
circulating, to UV radiation results in the formation of blisters, lesions and excessive fragility 
[24].  
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The build-up of excessive ALA and PBG, the porphyrin precursors, however, places patients 
at risk for the life-threatening neurologic pathology known as the ‘acute attack’ [25]. These 
acute attacks are found in the majority of patients to cause symptoms including severe 
abdominal pain, nausea, and vomiting, as well as hypertension and tachycardia. In addition, if 
unrecognised and untreated, it may result in profound sensory and motor neuropathy resulting 
in paralysis [26,27].  The attacks may be triggered by various factors, including porphyrinogenic 
drugs that induce the haem biosynthesis cycle, changes in hormonal levels (which is 
specifically a problem with women and their menstrual cycles), smoking or alcohol, as well as 
the induction of the haem oxygenase following prolonged periods of fasting or with a fever 
[28,29]. These factors may up-regulate expression of ALAS directly or result in the further 
induction of the haem biosynthesis pathway, which, in the case of porphyria, is an already 
compromised system.  This places further stress on the pathway and with the continued build 
up of ALA and PBG as the system fails to produce haem, the acute attack is triggered.  The 
only currently available option for treatment of these symptoms is the intravenous 
supplementation of haem with haem arginate.  This allows for the bypassing of the cycle, and 
the supplemented haem may act on ALAS1 to suppress the cycle, thus preventing further 
build-up of the hazardous and potentially fatal porphyrin precursors, ALA and PBG [24,28]. 
Liver transplants in patients with AIP or VP, who experienced severe and frequent attacks, 
have shown to be successful in a few cases. Their ALA and PBG levels returned to normal 
levels following 24 hours post-transplant, and there were no reports of subsequent attacks 
[30,31].  However, a liver transplantation is a high-risk procedure, and is only considered as a 
last resort [32].   
 
Classification of the Porphyrias 
The porphyrias are generally classified as acute or cutaneous depending on the presence or 
absence of acute attacks [33]. The cutaneous porphyrias include, X-linked protoporphyria 
(XLDPP), congenital erythropoïetic porphyria (CEP), erythropoïetic protoporphyria (EPP), 
hepatoerythropoïetic porphyria (HEP) and porphyria cutanea tarda (PCT), whereas the four 
acute porphyrias are: acute intermittent porphyria (AIP), δ-aminolevulinic acid deficiency 
porphyria (ADP), hereditary coproporphyria (HCP) and variegate porphyria (VP) [34,35].   
 
From a clinical perspective, the classification according to the risk of acute attacks is preferred, 
however, there are two alternative ways of grouping the porphyrias - either according to the 
origin of the porphyrin precursors or intermediate build-up (hepatic or erythroid), or by the mode 
of inheritance (dominant, recessive, autosomal or sex-linked) [32]. From a biochemical point 
of view, it makes sense to classify the porphyrias simply by the specific enzyme deficiency – 
thus VP would be PPOX-deficiency porphyria, AIP a PBGD-deficiency porphyria and so on.  A 
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simplified overview of each of the enzymes within the pathway and the respective porphyria is 
shown in Figure 1.3. 
 
Figure 1.3 A representation of porphyria subtypes and the associated enzyme defects [9].  The 
enzyme involved in each step is denoted in red. The enzymes are described as follows: (ALAS)- 
aminovulenic acid synthase; (ALAD) – aminovulenic acid dehydratase; (PBGD) – porphobilinogen 
deaminase; (UROS) – uroporphyrinogen III synthase; (UROD); uroporphyrinogen decarboxylase; 
(CPO) – coproporphyrin oxidase; (PPOX) – protoporphyrin oxidase; (FC) – ferrochelatase. 
 
Diagnosis of the Porphyrias 
Porphyria is often misdiagnosed in patients, usually for two reasons.  Firstly, the disease itself 
is rare, presenting with a low penetrance (patients presenting with symptoms), and therefore 
a differential diagnosis might overlook the porphyria symptoms for another, more commonly 
occurring disease [22,23].  Secondly, the phenotype of patients is not always consistent, and 
clinical manifestations vary from patient to patient [38].  Symptoms are rarely overtly present 
in patients with porphyria, and are normally only seen after puberty. Also, a great proportion of 
patients remain asymptomatic for their entire life [39,40]. As mentioned, each porphyria has a 
characteristic biochemical porphyrin excretion pattern, depending on which enzyme is 
defective. Biochemical analysis of urine and or stool samples may provide an indication of 
porphyria.  In acute porphyrias, the levels of PBG are measured in the urine, followed by 
subsequent urine and or stool analysis in order to determine which specific acute porphyria is 
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suspected [24,32]. Following a biochemical analysis, DNA may be obtained from patient blood 
samples for genomic (DNA) screening.  This is also very useful for when gene mutation(s) 
have already been identified in a specific porphyric family, and thus one may usefully employ 
gene screening as the first line method of choice in establishing a porphyria diagnosis [41,42].  
However, the other side of this double-edged sword is, that even when differential diagnoses 
of suspected cases are made, biochemical analysis from the blood, urine and/or stool often 
show inconclusive results [43–45].  This illustrates the need for molecular analysis of this rare, 
yet complex, disease. 
 
The Need for Molecular Analysis 
Molecular analysis may be done in two ways. Firstly, as mentioned, by performing genomic 
(DNA) screening of patients suspected to suffer from porphyria. Here, the biochemical 
analysis, although perhaps inconclusive as a single test, may serve to aid the genomic 
screening by indicating the levels of the elevated porphyrin precursors (ALA and PBG) and 
other intermediates, in order to determine a starting point for which gene within the pathway to 
screen for mutation(s) [46].  
 
The second method of molecular analysis is at the protein (enzyme) level.  Defects within one 
enzyme lead to the phenotype of a particular porphyria, however, different mutations within the 
gene, result in different expression, conformations and ultimately efficacy of the enzyme. For 
example, a simple “T” nucleotide insertion within an exon may result in the generation of a 
premature stop codon.  Consequently, the gene is only partially expressed, resulting in a 
truncated, non-functional enzyme [47].  In another example, one mutation might affect the 
enzyme’s kinetic behaviour and affect the ability to produce a product from its substrate (i.e. 
the enzyme’s specific activity and/or catalytic efficiency). Another different point mutation, 
located near the protein surface may expose the enzyme’s hydrophobic areas, thus resulting 
in conformational defects, again with impaired functionality.  
 
Analysis of the protein structure leads to a better understanding of the enzyme mechanism, 
and thus the disease itself, which potentially allows for ‘bridging of the gap’ between 
inconclusive biochemical analyses, genomic mutation identification and the often misleading 
clinical phenotypes [48].   
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Acute Intermittent Porphyria 
Overview 
Acute intermittent porphyria (AIP) is one of the acute porphyrias that results from a genetic 
defect within the third enzyme of the haem biosynthesis pathway, porphobilinogen deaminase 
(PBGD), also referred to as hydroxymethylbilane synthase (HMBS) [45]. AIP is the most 
commonly occurring acute porphyria world-wide, and also the best described in terms of 
enzymatic (PBGD) function and characterisation [49].  
 
AIP most often exists as a clinically latent disease, in which patients rarely present with overt 
symptoms of the disease. In fact, a majority of AIP patients (80%) appear to remain 
asymptomatic throughout their lifetime [50].  Furthermore, as mentioned, clinical expression of 
the disease is dependent on multiple factors including nutritional, hormonal, as well as 
environmental factors that could place pressure on the haem synthetic pathway [43]. Presently, 
as of January 2016, a total of 403 mutations in the in the PBGD enzyme have been submitted 
to the by The Human Mutation Genome Database (HMGD®) [51].   
 
The HMBS Locus 
The HMBS gene has been studied extensively since the early 1980s. Raich et al. (1986) first 
cloned the cDNA of erythroid PBGD from human tissue and deduced the protein size as 344 
amino acids [52]. Further studies revealed that two isoforms of the enzyme exist, the erythroid 
specific form, and the ubiquitously expressed form [53,54]. The human HMBS gene was 
mapped to the long arm of chromosome 11 (11q24.1→q24.2), spanning a total of 15 exons 
and a genomic interval of 10kb [26,55].  
 
Figure 1.4  The structure and organization of the HMBS gene on chromosome 11.  Exons are shown 
as black boxes. The labelling NE specifies the non-erythroid promoter for the ubiquitous expression of 
PBGD, with the transcription start site (ATG) located within exon 1, whereas E specifies the erythroid 
promoter with the erythroid isoform transcription start site (ATG) within exon 3 as adapted from reference 
[56]. 
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The ubiquitous isoform of the enzyme is the larger, having a total of 361 amino acids, whereas 
the erythroid isoform has a 17 residue shorter N-terminus, is comprised of 344 amino acids, 
and is only expressed in erythroid specific cells and tissues [26]. As shown in Figure 1.4, the 
non-erythroid (ubiquitous) form of the PBGD enzyme is transcribed from the transcription start 
site found in exon 1, whereas the erythroid form has a downstream erythroid specific promoter 
within intron 2 and transcription is initiated from exon 3 [53,54,56]. 
 
The alternative forms of the PBGD enzyme are produced by alternative splicing of the HMBS 
gene (Figure 1.5). In the ubiquitous (non-erythroid) form (ENST00000278715), the second 
exon is spliced out and the mRNA transcript is comprised of 14 exons, a total length of 1501 
bp and encodes the 361 amino acid enzyme [26].  In the erythroid form (ENST00000392841), 
however, exon 2 is spliced to exon 3 and transcription is only initiated within exon 3, with the 
erythroid mRNA thus being comprised of 14 exons, a total length of 1411 bp and encoding the 
344 residue form of PBGD [56,57]. 
 
Porphobilinogen Deaminase 
Porphobilinogen deaminase (EC 2.5.1.61; or hydroxymethylbilane synthase) catalyses the 
hydrolysis and subsequent condensation of four molecules of PBG to form the linear 
tetrapyrrole hydroxymethylbilane (Figure 1.5) [14].   
Figure 1.5   The reaction catalysed by Porphobilinogen Deaminase (PBGD) whereby four molecules of 
porphobilinogen (PBG; ChEBI_17381) are fused together to form the tetrapyrrole hydroxymethylbilane 
(HMB; CHEMBL273676). Image and reaction generated by ChemSketch, Version 2.0 [5]. 
 
 
One of the characteristic features of the PBGD enzyme is the permanently bound 
dipyrromethane co-factor, attached to the enzyme via a thioether bond at the cysteine 261 
residue within the active site. The dipyrromethane is comprised of the PBG molecules, and is 
responsible for the stability of the enzyme [58].  
  
porphobilinogen 
Porphobilinogen Deaminase 
Hydroxymethylbilane 
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Normally, PBGD catalyses the reaction that initiates the formation of the pyrrole ring by 
hydrolysing, and subsequently condensing four PBG molecules to form the first tetrapyrrole in 
the pathway, hydroxymethylbilane (HMB) (Figure 1.2). HMB is a linear tetrapyrrole which 
undergoes cyclization in the next step, to form the prerequisite cyclic porphyrin tetrapyrrole, 
which is the chemical precursor of haem.  In patients with AIP, however, the enzyme usually 
only has approximately 50% of its activity, placing patients at risk of an acute attack, as failure 
of the PBGD to convert and utilise the PBG may result in increased levels of PBG in the cell 
[27,59].  
 
Protein Structure 
The enzyme exists as a monomer with the non-erythroid monomeric enzyme form having a 
molecular weight of between 34 and 44 kDa, depending on the species. For the human 
enzyme, the molecular size is the 44 kDa for the ubiquitous (or housekeeping isoform), and 42 
kDa for the erythroid specific isoform [60]. The PBGD monomer is comprised of three distinct 
domains as shown in Figure 1.6. Several PBGD crystal structures from a variety of species 
have been solved at high resolution (Table 1.1).  
 
 
 
 
Figure 1.6 The PBGD (EC 2.5.1.61) monomer with its three domains and the dipyrromethane (DPM) 
co-factor within the enzyme active site. (PDB accession number 3EQ1). Image Generated by UCSF 
Chimera package [61]. 
 
 
  
DPM co-factor 
Domain III 
Domain I 
Domain II 
N-terminus 
C-terminus 
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Table 1.1 A summary of the crystal structures available for the PBGD enzyme on the Protein 
Database (PDB). # Highlighted residues indicated in brackets are the representative residue number in 
the human enzyme. 
Year Authors Species PDB Å Detail Highlighted Residue(s) 
 
1992 
Louie et 
al. 
E. coli 1PDA 1.76 
First reported structure of 
PBGD, illustrating the 3 
domains, the hydrophobic core, 
hydrogen bonding and crucial 
interaction of the DPM co-factor 
[62]. 
 
1998 
Helliwell 
et al. 
E. coli 1YPN 2.40 
Time-resolved structures of 
hydroxymethylbilane synthase, 
as it is loaded with substrate in 
the crystal determined by Laue 
diffraction [63]. 
K59Q (K57Q)# 
 
1999 
Nieh et 
al. 
E. coli 2YPN 2.30 
Accurate and highly complete 
synchrotron protein crystal Laue 
diffraction data using the ESRF 
CCD and the Daresbury Laue 
software [64]. 
 
1999 Hädener 
et al. 
E. coli 1AH5 2.40 
The crystal structure of the 
selenomethionine-labelled 
enzyme ([SeMet]HMBS) from 
Escherichia coli solved by 
means of multi-wavelength 
anomalous dispersion (MAD) 
experimental method [65]. 
 
 
2003 
Helliwell 
et al. 
E. coli 1GTK 1.66 
Time-resolved and static-
ensemble structural chemistry of 
hydroxymethylbilane synthase 
[66]. 
 
 
2009 
Gill et al. Homo 
Sapiens 
3EQ1 2.80 
The structural and functional 
implications of the R167Q 
mutation is discussed [60]. 
R167Q 
 
2009 
Song et 
al. 
Homo 
Sapiens 
3ECR 2.18 
Structural insights into the 
mechanism of action of PBGD at 
the molecular level [67]. 
S96; D99; 
H120; L238 
C261; 
2013 Roberts 
et al. 
Aradopsis 
thaliana 
4HTG 1.45 
Proposed modelling of the 
intermediate of the elongation 
process. [68,69]. 
D95 (D99)#; 
C254 (C261)# 
2014 
Azim et 
al. 
Bacillus 
megaterium 
4MLV 
4MLQ 
1.60 
1.46 
Illustrates how the DPM co-
factor becomes progressively 
oxidised to the dipyrromethene 
and dipyrromethenone forms, 
rendering the enzyme inactive 
[70,71]. 
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The three domains of the PBGD enzyme are all approximately the same size (Figure 1.6) [70].  
The N-terminal domain (domain I) is made up of 3 anti-parallel and 2 parallel beta sheets 
surrounded by 3 helices. In addition, it consists of numerous loops that form a cap-like structure 
which covers the active site [67]. Domains I and II are structurally related, and the active site 
is situated in the cleft between them.  The general architecture of domains I  and II have been 
suggested to resemble another protein family known as the periplasmic binding proteins [72].  
Such proteins adopt ‘open’ and ‘closed’ conformations, in response to ligand binding.  This 
might be a possible explanation for how the enzyme is able to accommodate the growing 
pyrrole chain within the active site cleft, release a tetrapyrrole product and revert to a ‘closed’ 
conformation for the next cycle.  Hence, Song et al. (2009) suggested that for the enzyme to 
be able to incorporate the growing pyrrole chain, there has to be a mechanism involving open 
and closed conformations.  It was predicted that there are three integral residues that allow for 
the hinge amongst the three domains.  These were His 120, Ser 96  and Leu 238  [67]. Roberts 
et al. (2013) corroborated the hinging mechanism suggesting that the lack of inter-domain 
connections between domain I and II highlights the possibility of their independent movement. 
It is important to bear in mind that the largest number of inter-domain contacts are mediated 
by the DPM co-factor, and so movement of the co-factor may result in movement of the 
domains. 
An interest and focus on the structure of PBGD has continued since the first early 
considerations of its structure in 1992, until the present. As highlighted in Table 1.1, the 
structure published in the Aradopsis thaliana was the first to be generated from a higher order 
species of plants. Based on the near atomic resolution of their PBGD crystal, a loop that covers 
the active site was observed however, in all previous structures, this could not be resolved 
from diffraction data [68].  Roberts et al. (2013) also focused on the polymerization of the 
pyrrole rings by the enzyme and its covalently bonded co-factor, and suggested a new thought 
on an old hypothesis.  Louie et al. (1992) suggested two possible theories of the enzyme 
mechanism based on the Escherichia coli (E.coli) crystal structure (which is discussed below) 
[62,72]. An alternative opinion was discussed by Azim et al. (2014), who published a crystal 
structure for PBGD in the bacterium Bacillus megaterium. The focus of their paper was to 
report on the oxidation states of the DPM co-factor and to determine 1) how it occurs and 2) 
what effects and/or consequences it may have (discussed in detail below). 
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The Active Site 
 
 
Figure 1.7 An illustration of the architecture within the PBGD enzyme’s active site, generated by UCSF 
Chimera package from the minimised crystal structure 3EQ1 [60,61]. Highlighted residues indicate those 
relevant in the DPM co-factor binding. 
 
The active site of the PBGD enzyme is very sophisticated, allowing for the permanent addition 
of the DPM co-factor as well as being able to adapt in order to accommodate the growing 
tetrapyrrole chain, [66,73]. Several key residues within the active site play an important part in 
maintaining the active site organization, forming of polar interactions amongst each other, and 
being essential for enzyme catalysis, as illustrated in Figure 1.7 [67,74].  The majority of the 
active site is populated with arginine residues, thereby resulting in a largely positively niche, 
providing an interface for ionic interactions between different residues and chains, the DPM 
co-factor, as well as incoming substrate (PBG) molecules [74]. Indeed, most reported 
mutations, if not all, of these residues within close proximity of the active site are known to be 
associated with the occurrence of AIP in humans [75,76].  The only covalent interactions within 
the active site are the cysteine 261 (C261) bonded to the DPM co-factor, and the bond 
formation of the pyrrole chain on each successive terminal ring.  The remainder of the 
interactions are mediated by van der Waal’s forces, salt bridges and hydrogen bonds [77].   
This is a clear indication why mutations within any of these residues ultimately result in disease 
as any changes to the network of interactions within this active site cleft is bound to disrupt the 
required interactions, or alternatively generate different interactions, which may disrupt the 
enzyme’s normal function [60].  
  
C261 
R149 
D99 
R150 
R173 
R195 
Q34 
K98 
C1 
C2 
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The DPM Co-Factor 
The DPM co-factor has been extensively studied, since its first discovery in the late 1980s, 
when Warren and Jordan (1987) provided preliminary evidence for the existence of this 
dipyrromethane within the active site cleft [78]. In the same year, Hart et al. (1987) 
demonstrated that the novel group within the enzyme active site (which was initially termed 
group X), was indeed dipyrromethane [79]. Prior to this discovery, there were several theories 
as to how the enzyme is actually able to polymerize subsequent PBG molecules.    
 
Previous studies suggested that PBG itself was bound to either lysine or cysteine, but the 
question remained as to how the enzyme was able to form stable intermediates during this 
substrate polymerization [78]. With the evidence presented by Hart et al. (1987) it was then 
clear that the tightly bound pyrrole was a permanent feature of the PBGD enzyme [79,80].  Of 
course, subsequent questions were raised regarding the origin of this novel binding group as 
well as the binding of the co-factor to the enzyme.  In 1988, two groups published papers at 
roughly the same time, both of which provided evidence that the co-factor was bound to Cys 
261 within domain III [81,82]. Figure 1.8 shows an illustration of the DPM co-factor structure 
as well as a model from the human enzyme crystal depicting the organization and orientation 
within the active site. 
 
 
Figure 1.8 An illustration of the DPM co-factor and its position in the PBGD enzyme. (I) Shows the 
chemical structure of the dipyrromethane generated from the ChEBI file for DPM (ChEBI_42121) in 
Chemsketch Version 2.0 for Windows [5]. (II)  Shows the orientation and architecture within the PBGD 
enzyme’s active site, generated by UCSF Chimera package from the minimised crystal structure 3EQ1 
[60,61]. 
 
With regards to the origin of the dipyrromethane co-factor, there are two theories. The first is 
that the co-factor is generated from the PBG substrate molecules in a first cycle, followed by 
subsequent polymerization, resulting in a hexapyrrole, with the HMB tetrapyrrole cleaved off 
and released as a product, whilst the remaining dipyrrole remains attached to the enzyme as 
the DPM co-factor. Although this has evidence to support this idea, the results also suggest 
I II 
C1 C2 
C1 
C2 
C261 
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that process is quite slow [83].  The second theory was put forth by Shoolingan-Jordan et al. 
(1996) in which they illustrated that the assembly of the DPM co-factor is done by the reaction 
of the preuorporphyrinogen product with the ‘apo’ PBGD enzyme [84].   In their work, they also 
argue that co-factor assembly is possible with the addition of only the PBG substrate 
molecules, however, the reaction proceeds very slowly, and the recovery of holoenzyme was 
very low (between 10 – 40% of normal enzyme activity).  Their proposed alternative theory 
was that the product of the enzyme, HMB, which is also referred to as preuroporphyrinogen, 
is the ideal precursor for the formation of the DPM co-factor in vivo [68,84]. In other words, the 
preuroporphyrinogen, which is comprised of four tetrapyrroles, acts as the DPM co-factor 
precursor, attaching to the cysteine 261, thereby illustrating the ES2 complex, followed by the 
addition of two further substrate (PBG) molecules to generate ES4. This is then followed by the 
release of the ES4 product, with the dipyrrole remaining permanently attached to the enzyme.   
The principle is illustrated below in Figure 1.9. 
Figure 1.9 The proposed mechanisms by which the PBGD enzyme may acquire the DPM co-factor, 
as adapted from [84]. Legends as follows: E(apo) – PBGD with no bound co-factor; E(holo) – PBGD 
with bound co-factor; ES – PBGD with one PBG: ES2 – PBGD with 2(PBG); ES3 – PBGD with 3(PBG); 
ES4 – PBGD with 4(PBG). 
 
With regards to the oxidation of the co-factor, the characteristic pink colour of the DPM co-
factor was initially suggested to be pyrrole intermediates.  There was also speculation that it 
could be the concentration of endogenous PBG in protein samples that leads to the pink 
chromophore.  However, the recent X-ray crystallographic studies have investigated the 
oxidation states of the co-factor [70,71].  It is known that purified PBGD enzyme loses the 
bright pink colour and becomes progressively orange over a period of time, resulting in a pale 
orange-yellow solution [69].  
 
This colour change is accredited to oxidation of the co-factor (Figure 1.10).   Indeed it was 
shown that the α-position of the C2 ring is sensitive to oxidation, and the oxidized 
dipyrromethane pyrrole, or rather dipyrromethenone, is catalytically inactive, as the carbonyl 
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oxygen at this point blocks the addition of new pyrroles. In addition, this process is irreversible, 
and the addition of reducing agents to prevent and/or terminate the oxidation inevitably failed. 
 
Figure 1.10 DPM co-factor oxidation (I) Shows the chemical structure of the dipyrromethane (as 
before) generated from the molfile for DPM (ChEBI_42121) in ChemSketch Version 2.0 for Windows 
[5]. (II) The proposed bound-oxidised cofactor, dipyrromethenone, illustrating the carbonyl oxygen at the 
C2 ring.  
 
Highlighted Residues for Co-Factor Interaction 
The most important interactions have been suggested to be residues containing pyrrole 
nitrogen(s) (N) that can form a hydrogen bond with the carbonyl oxygen atoms from the co-
factor [68]. For example, the R131L and R132L mutations have been shown to affect the 
binding of the DPM co-factor. This is as a result of the change in charge from the positive 
arginine (R) to the neutral leucine (L).  Therefore the ionic interaction between the negative 
carbonyl groups of the co-factor and the positive amine groups in the arginine side chain is 
lost, rendering the enzyme inactive [77]. Indeed, there are several other residues, including 
the K98, D99, C261, R150, R173 and the R195, which have been suggested to be involved 
with the DPM co-factor interaction [67]. Several residues have also shown to be important for 
both enzyme catalysis as well as co-factor orientation.  R149 as well as D99 mutations indicate 
a loss of co-factor interaction, although they are considered key catalytic residues [85].  
 
PBGD Enzyme Mechanism 
PBGD is able to form stable intermediates during substrate polymerization, also referred to as 
chain elongation [78]. Figure 1.11 provides a simplified illustration of the process, whereby 
each successive PBG molecule is added to the enzyme-co-factor complex, in a stepwise 
manner [48,82]. The complexes are generally referred to as ES, with one PBG molecule 
added, ES2 depicting two PBG molecules, similarly with ES3 and ES4.  As illustrated in Figure 
1.11, the PBG molecules are added to the enzyme in a head-to-tail fashion, with the free alpha 
carbon on the C2 ring of the DPM co-factor acting the source for nucleophilic attack in order 
to form the bond [74]. 
I II 
C1 C2 
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Figure 1.11 An illustration of the PBGD enzyme mechanism, illustrating the polymerization of the PBG 
substrate in each successive step, as adapted from [74]. Image was generated in ChemSketch Version 
2.0 with the use of the Molfiles for PBG and the DPM co-factor, ChEBI_17381 and ChEBI_42121 
respectively. The lettering as follows: A: acetate (-CH2CO2H) and B: propionate (-CH2CH2CO2H). 
 
There has been much debate regarding the mechanism for this pyrrole chain elongation.  As 
mentioned earlier, the first two proposals were put forward by Louie et al. (1996) following the 
first successful crystal structure of PBGD in E.coli. Their first hypothesis was what is referred 
to as the “active site model”, in which the growing pyrrole chain is accommodated in the active  
site cleft, and the three domains adjust themselves accordingly in order to facilitate the binding 
of each subsequent pyrrole, whereas the second hypothesis, referred to as the “moving chain 
model”, suggests that the developing chain is progressively “pulled” across the catalytic site, 
thereby placing the terminal binding rings within the substrate binding site [72].  
 
Roberts et al. (2013)  built on this model, with their proposed  “novel mechanism”  following 
observations from their crystal structure [68].  Their mechanism for polymerization included 
that the co-factor was in its oxidised form in order to incorporate the growing pyrrole chain 
within the active site cleft.  Their argument was that the oxidised conformation of the DPM co-
factor acquires a different structural orientation when compared to the reduced form, and this 
oxidised form allows for additional movement and generation of space in the active site cavity.  
This concept on its own is true, in that, based on their modelling and predictions, the active 
site does open up more once the co-factor is oxidised.  This was also suggested by Louie et 
al. (1996), illustrating two conformations within the active site, one with reduced co-factor, and 
the other with the oxidised form [72].  However, they did not consider what effect the oxidation 
α 
C2 C1 
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state of the co-factor would have on the activity and catalytic mechanism of the enzyme itself.  
This clearly illustrates one of the limitations of crystallography.  Although it provides insight into 
the structure and architecture of the enzyme and its parts, it remains a static picture of a 
dynamic system. In addition, the crystallisation conditions are not necessarily equivalent to in 
vivo conditions. This was proven by Azim et al. (2014) who showed that the co-factor is 
sensitive to oxidation, and that this oxidation renders the enzyme inactive [70].  Furthermore, 
it is irreversible, and no attempt to ‘salvage’ the enzyme with re-addition of reducing agents or 
attempts to prevent oxidation proved viable.  This answered the questions raised by Roberts 
et al. (2013), as their theory also includes the hypothesis that the co-factor may shift between 
reduced and oxidised states during pyrrole elongation [69]. 
 
Bung et al. (2014) published a paper following the suggestions made by Roberts et al. (2013), 
in which they performed molecular dynamics on the PBGD enzyme, in order to clarify the 
hypotheses and proposals of the mechanism based on crystal structures [77].  Molecular 
dynamics involves the computational modelling of the movement of atoms and bonds within 
an enzyme in order to predict how ligands may interact with a protein [86,87]. Bung et al. (2014) 
classified the mechanism of the enzyme as operating in three stages. Firstly, chain elongation, 
forming the tetrapyrrole product. Secondly, the exit of the HMB product from the active site 
cavity, and finally the relaxation of the enzyme following product release.   
 
With regards to the chain elongation, it was found that the active site loop (residues 42 – 60 in 
the E.coli PBGD) as well as domain II, adjust their conformations to widening the active site 
cleft, in order to accommodate for the growing pyrrole chain (referred to as the ‘open’ 
conformation). Interestingly, they also found that the space occupancy for the entire 
tetrapyrrole product was adjusted for by the active site loop, and minimal structural changes 
were observed for the protein as a whole. In addition, when comparing the secondary structure 
of the domains from the first stage, where no substrate was bound (E), to the final stage that 
included the bound tetrapyrrole product (ES4), noticeable changes were observed, specifically 
between domains I and II.  This suggested that there was a widening of the gap between the 
two domains as the chain elongation progresses.  
 
Highlighted Residues for Enzyme Function 
Studies suggest that mutations in the active site arginine residues have an effect on enzyme 
mechanism [74,88].  The mutations, R11H, R149H, R155H, R176H and R232H all cause 
disruption in the formation of the HMB product.  The alteration of all of these residues to 
histidine (H) causes steric disruption as rotation of the cyclic bonds in histidine is limited in 
comparison to bond rotation within arginine (R).  It is also possible that the bulky ring from the 
histidine causes disruption of surrounding residues [74].  
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In terms of product release/exit, the molecular dynamics and simulations suggest that the HMB 
product exists between the space of Domain I and II and the active site loop. Finally, structural 
changes between the last stage following product release and the original form suggested, 
protein ‘relaxation’, thus allowing for the active site to re-assume the ‘closed’ conformation, 
and prepare for the next cycle [77]. The significance of the molecular modelling is that it 
provides an analysis of the enzyme’s dynamic features [89].  Although the analysis of the 
PBGD crystal structures have been significant in that it allowed for discovering the residues 
important for catalysis and for speculation regarding how the structure correlates to the enzyme 
function, the crystal does not contain the substrate (ES complex). Whereas with the molecular 
dynamics, it allows for the analysis of each of the stages (as depicted in Figure 1.11) [77]. 
 
The R149 residue has been shown to be involved with forming a network of hydrogen bonds 
with the K98 and D124 within the active site [85]. Thus, mutations of R149 may result not only 
in failure of catalysis, but disrupt additional residue interactions.  Lysine has also proven to be 
important for the enzyme’s catalytic function, as K62 and K59 mutations to glutamine (Q) have 
been reported to result in disturbances in the enzyme’s catalytic efficiency [64,77,90]. Several 
other residues in the active site vicinity have been shown to be highly conserved in a range of 
different species, pointing to their potential role in enzyme function and/or confirmation.  The 
D99 residue has been highlighted in several cases as being the major catalytic residue of the 
active site, and is shown to be involved with each of the polymerization steps during chain 
elongation [67,85]. 
 
Highlighted Residues for the Exit Mechanism  
It has been suggested that the movement of the active site loop that falls between domains I 
and II guided by strong interactions of neighbouring residues, plays a key role in the catalysis, 
including the exit of the HMB product. In addition, residues R26, Q34, K98 and R196 have 
been suggested to aid the movement of the product towards the cleft of domains I and II [77]. 
The D99 residue has been suggested to play a role in the final hydrolysis reaction, whereby 
the HMB product is cleaved from the co-factor [68]. 
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Lysine 98 
The Lysine 98 (or K98) is a highly conserved residue within the PBGD enzyme active site, as 
illustrated below in Figure 1.12.  It has also been shown to be conserved in several other 
species [67,70]. In addition, it has been suggested throughout the literature as being a key 
residue for several stages of the enzyme function [67,68,77].  However, in all of these cases 
the significance of the K98 residue is based on speculation, the vicinity to the active site and 
also the proximity to nearby residues D99 and R195. No further detail as to why this residue 
could be important is suggested. Generally there is a failure to mention how exactly this residue 
interacts further with neighbouring residues in terms of structural orientation, and only 
speculation in terms of the contribution of this residue to the DPM co-factor interaction 
[42,45,64]. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.12  The multiple sequence alignment of PBGD in different species.  Conserved residues are 
indicated by the (*).  The K98 residue is indicated by the arrow.  
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Study Rationale 
As there is a clear indication that the K98 residue plays a key role in several stages of the 
enzyme mechanism, we developed an interest in furthering our knowledge around this residue. 
This may provide insight into our understanding of the role this residue specifically plays within 
the enzyme active site. Like other studies we believed that we could gain insight by mutating 
this residue and analysing the effect(s) of such. A previous M.Med student from our laboratory 
discovered a K98E mutation in a South African AIP family (personal communication, P 
Fortgens, AV Corrigall and PN Meissner).  Furthermore, a K98R mutation has been 
documented in a patient in 1991. However, no further analysis on this mutation was performed 
[91]. From our work in 2013, we have preliminary evidence that suggests that mutations in the 
K98 residue cause disruptions to the enzyme’s kinetic behaviour. Thus, apart from an interest 
in better understanding PBGD at a basic level, our interest in the K98 residue was born out of 
the clinical realm, and an on-going interest in porphyria disease-causing mutations.  
 
Our aim therefore, and the purpose of this study, was to elaborate on current information 
regarding the characteristics of the PBGD enzyme, by investigating how mutations within the 
active site affect the enzyme mechanism as well as conformation. Indeed, further mutations at 
residues like K98, as well as other structurally identified/important sites, could improve our 
understanding and may allow us to further elucidate the complex mechanism of the PBGD 
enzyme. 
 
In chapter 2 of this dissertation, I describe our methodology and approaches to the kinetic and 
structural characterisation. Included are explanations of the specific protocols developed for 
the study, as well as optimization strategies that were required for expression and purification 
of the recombinant enzymes.  
 
Chapter 3 presents and describes the results of this study. In several cases data is represented 
in both a graphical and table format.  This was to allow not only for quantitative presentation, 
but also a more visual and qualitative overview, when comparing the wild type PBGD to the 
recombinant enzymes. 
 
Finally, in Chapter 4, I provide an in-depth discussion of each section of results, and an 
integrated discussion and depiction of each of the different mutations. We conclude and 
provide an overview of future directions for this work.  
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Specific Research Question 
Do PBGD Lysine 98 (K98) mutants affect enzyme function and if so, what are the likely 
underlying molecular mechanisms and explanations of such dysfunction? 
 
Aims 
 
1. To engineer a series of K98 mutant PBGD enzymes by site directed mutagenesis. 
Objectives: 
• Design primers that will incorporate the desired mutation within the HMBS gene. 
• Perform a site directed mutagenesis PCR reaction followed by a DpnI restriction 
endonuclease digest in order to eliminate any template DNA. 
• Transform mutated sequenced DNA into JM109 supercompetent E. coli cells. 
• Plate transformed cells onto prepared Agar plates and select colonies for inoculation. 
• Incubate selected colonies in order to extract DNA for sequencing. 
• Verify which selected colonies have incorporated the desired mutation by means of direct 
sequencing. 
2. To perform an activity and kinetic characterisation on the engineered, expressed and 
purified PBGD K98 mutants. 
Objectives: 
• Inoculate large scaled batched of media in order to express and purify the selected 
mutations. 
• Establish purification protocol for newly generated mutant. Purify each of the mutants in 
parallel with wild type. 
• Set-up and analyse the kinetic profile of each of the mutants and correlate to the wild 
type protein. 
3. To perform a native polyacrylamide gel electrophoresis (PAGE) analysis of purified 
PBGD K98 mutants in order to observe enzyme-substrate (ES) complexes. 
Objectives: 
• Purify wild type and each of the K98 mutants. 
• Establish a protocol that allows for successful visualisation of wild type ES bands on 
native PAGE gels. 
• Perform a native PAGE and verify whether any of the mutations result in changes in the 
electrophoretic behaviour of the enzyme complexes. 
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4. To analyse the effect of mutating K98 in terms of the enzyme’s DPM co-factor. 
Objectives 
• Set up the spectrophometric analysis to observe co-factor binding. 
• Correlate mutation co-factor binding to wild type enzyme. 
5. To attempt to remove the bound dipyrromethane co-factor from wild type enzyme. 
Objectives: 
• Set up and perform an assay to remove the bound dipyrromethane from the native wild 
type enzyme. 
• Confirm the successful removal of the enzyme’s co-factor (as in 4. above). 
• Set up and establish a reconstitution assay, to test the enzyme’s ability to accept co-
factor versus the PBG substrate. 
6. To gain structural insights into wild-type PBGD and K98 mutants using 
conformational and thermodynamic characterisation assays. 
Objectives:  
• Purify each of the respective mutants in parallel with wild type enzyme. 
• Set up and establish a protocol for measuring the Far- and near- UV circular dichroism 
spectra for each of the mutants. 
• Determine the secondary structure estimations for each of the mutants by means of 
several structural algorithms (CDPro, CDNN, DSSP and STRIDE). 
• Set up and perform a thermal assay for each of the samples. 
• Fit data to a two-state unfolding plot and determine the melting temperature for each of 
the mutants and compare to wild type. 
• Determine the conformational stability of each mutant by measuring the fraction of 
unfolded protein of each mutant and comparing it to wild type. 
7. To model the K98 mutant proteins from a structural perspective and attempt to 
reconcile the structural analysis with the kinetic and thermodynamic data. 
Objectives: 
§ To generate a collective enzyme structure from available PDB crystal structure files, in 
order to have an accurate depiction of enzyme structure (including missing loops). 
§ Minimizing the superimposed-aligned structure of the enzyme in order to have the 
lowest energy calculations. 
§ Model each of the mutations to the prepared crystal structure of the PBGD enzyme and 
observe possible alterations and/or explanations that correlate to the kinetic and 
thermodynamic data. 
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Introduction 
This chapter details the materials and methods employed for the experimental work. In general, 
this takes the form of presenting the principles on which the method is based followed by the 
procedure used in the lab. Where further detail is required the reader is referred to an 
appropriate appendix. 
 
Site-Directed mutagenesis 
Principle 
QuickChange® employs supercoiled, double-stranded plasmid DNA and two designed, 
synthetic primers containing the desired mutation in order to generate a mutation by means of 
the highly effective DNA polymerase PfuTurbo. Figure 2.1 below is an illustration of the 
mutagenesis principle, adapted from the Stratagene QuickChange® user manual.   
Figure 2.1 An illustration of the principle of QuickChange® Site Directed Mutagenesis. Step 1) The 
plasmid containing the gene of interest and the target site (X) for the mutation. Step 2) Denaturing of 
the plasmid to allow for annealing of the mutagenic primers ( ) containing the desired mutation. 
Following denaturation, allow the PfuTurbo DNA polymerase to extend and incorporate mutagenic 
primers.  Step 3) Digest the wild type parental template plasmid with DpnI. Step 4) Transform the 
circular, nicked dsDNA into JM109 supercompetent cells. These cells will then repair the nicks in the 
mutated plasmids.  
 
Procedure 
Wild type HMBS DNA was extracted from an overnight growth of an E.coli plasmid culture 
using the Wizard®  Plus SV Minipreps DNA Purification kit (Promega Corporation, Madison, 
USA) (detail given in Appendix 5). Mutagenic primers (also referred to as oligonucleotides) 
were designed complementary to the opposite strands of the plasmid, and extended, by the 
action of PfuTurbo during the temperature cycling. The products were then subjected to DpnI 
restriction endonuclease (RE) digestion, which cleaves and digests the parental template 
strand. The DpnI recognises the methylated sequence (5’-Gm6ATC-3’) found within DNA 
isolated from E.coli. This allows for the selection of only mutated plasmids. The mutated 
plasmid DNA was then transformed into supercompetent cells (JM109). The details of the 
mutagenic  
primers 
‘nicks’ within  
mutated plasmid 
Step 1 
Plasmid 
Preparation 
Step 2 
Temperature 
Cycling 
Step 3 
Digestion 
Step 4 
Transformation 
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protocol and precise methodology for this study are outlined in Appendix 9. Post transformation 
and plating, eight colonies were selected after an overnight incubation at 37⁰C and inoculated 
into 6 ml LB media (Appendix 3) containing ampicillin.  Samples were cultured in a shaking 
incubator at 37⁰C overnight. The selected samples were also re-plated, prior to LB inoculation, 
on another sterile agar plate, and incubated at 37⁰C overnight. Thereafter 30% glycerol stock 
solutions were made and stored at –80⁰C (Appendix 4). 
 
Screening Clones 
In order to screen the entire HMBS gene (Appendix 1), we designed two sets of primers 
(forward and reverse) using Primer Designer (Software Packaging version 2, Scientific and 
Education Software). The primers were designed to stretch from the vector into the HMBS 
gene insert and also from the insert to the vector (detailed in Appendix 2). This was done in 
order to enable screening for the desired mutation and also to ensure that no additional 
mutation(s) had inadvertently been introduced. The analysis software from Integrated DNA 
Technologies (IDT), Oligo Analyzer, was used to analyse the properties of the designed 
primers as follows: percentage GC content, melting temperature (Tm), ΔG, self-dimer, and 
hetero-dimer (Table 2.1). Primers were manufactured by Integrated DNA Technologies (IDT). 
Further details are outlined in Appendix 7.  
Table 2.1   Outline of the parameters set for the primer design. 
Parameter Minimum Maximum Optimum 
GC (%) 50 60 55 
Tm (⁰C) 70 80 74 
Gradient PCR was employed using wild type DNA to determine the optimum annealing 
temperatures and ensure specificity of the HMBS fragments (as outline in Appendix 2). The 
PCR was performed as described in Appendix 10. The plasmid DNA from overnight cultures 
of the engineered mutants was extracted using the Wizard® Plus SV Miniprep DNA Purification 
system (Appendix 5) and quantified (Appendix 6). The amplified PCR products were then 
loaded on a 6% non-denaturing PAGE gel (Appendix 11) in order to check the quality of the 
products. The online bioinformatics tool, Webcutter 2.0 (http://rna.lundberg.gu.se/cutter2/), 
was utilised to ascertain if a restriction site would be created/abolished by the engineering of 
the mutants. If so, a relevant restriction analysis was performed for easy screening of potential 
mutants. Only one of the engineered mutations, K98R, created a Bsm FI recognition site. 
Details for the restriction analysis are outlined in Table 2.2. 
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Table 2.2  Bsm FI (FaqI) restriction analysis. 
Reagent Final Concentration Volume (µl) 
PCR Product (non-purified)  5 
Buffer (10X) 1X 2 
Bsm FI (2U/µl) 1 0.5 
d.H2O  12.5 
 
Following digestion, products were loaded on a 6% non-denaturing PAGE gel (Appendix 11). 
As no cutting site was introduced/abolished by the engineering of the K98E and K98A 
mutations, 4 selected clones were sent for direct sequencing. Due to the high success rate of 
engineering mutations previously experienced in the UCT Porphyria laboratory it was not 
deemed necessary to design a primer that would create a suitable restriction enzyme cutting 
site. 
 
Confirmation of Mutated Sequences 
PCR products were purified by the IllustraTM GFXTM PCR DNA Purification kit (Appendix 12).  
DNA Sequencing was done by the Core DNA sequencing facility of the University of 
Stellenbosch using the BigDye Terminator sequencing kit, Version 3.1 (Applied Biosystems, 
Brachberg, USA) on either a ABI3130xl or ABI3730xl Automated Genetic Analyzer. Purified 
PCR samples were sent in 8 ng/µl concentrations and primers at 1.1 pmol/µl. In order to ensure 
proper screening of the entire fragment, sequencing was performed both in the forward and 
reverse direction. The mutated sequence was aligned to the known wild type fragment(s) 
(Appendices 1 & 2). 
 
Expression of wild type and mutant PBGD 
Wild type PBGD clones with a 6X-His tag plasmids have been used in our laboratory prior to 
this study. The PBGD containing pTrc His-A Vector plasmid we utilised was a gift from 
Professor Harry Dailey (University of Georgia, Athens, Georgia, USA). For PBGD expression, 
a 1 ml stock (Appendix 4) of PBGD was inoculated in 1L LB media (Appendix 3) containing 
ampicillin and incubated at 37¹C for 22 hours in a shaking incubator (225 rpm). In the case of 
our low expressing mutants, we inoculated a double-batch, thereby having 2L of inoculated 
media for K98R. For the K98A, the growth period was increased to 24 hours. 
  
   28 
 
Purification of wild type and mutant PBGD 
The TALONTM metal affinity resin protein purification system was used for the purification of 
both wild type and mutant PBGD. 
Figure 2.2 An illustration of the principle of the TALONTM metal affinity chromatography.  The carrier 
bead is attached to the talon structure containing the Cobalt metal ion (Co2+). Image is based on the 
concept from the Clonetech website [http://www.clontech.com][92,93].  Histidine (ChEBI:15971) residue 
was generated by ChemSketch, Version 2.0 [5]. 
 
Principle 
This purification system is based on the interaction and degree of affinity of histidine (with a 
high electron dense region) for Cobalt (Co2+), within the TALONTM resin. The positive oxidation 
state of Cobalt provides a means of interaction for the electron histidine-rich residues within 
the 6X-His tag (Figure 2.2). The His-tagged PBGD ‘sticks’ to the resin, allowing other non-
specific proteins to flow through. A wash buffer, with a low concentration of imidazole, is used 
to remove any non-specifically bound proteins. Finally, an elution buffer with a high 
concentration of imidazole is used to competitively elute the purified PBGD, as illustrated below 
in Figure 2.3. 
 
Procedure 
Briefly, cells were cultured from a 1L sample of medium, harvested by centrifugation and 
resuspended in a sonication buffer.  Cells were then lysed by sonication and lysate ultra-
centrifuged to yield a clear suspension.  The TALONTM resin was equilibrated and sample 
loaded onto the column at a flow rate of 15 ml per hour.  Flow through was collected (the void) 
and pooled.  The column was then washed with a minimum of 10ml wash buffer, before eluting 
TALONTM  
Resin 
TALONTM  
Structure 
Polyhistadine tag Protein 
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the bound protein with the final (elution) buffer. Phenylmethyldsulfonylfloride (PMSF) was 
added in a final concentration of 1 µg/ml to all purification buffers directly before addition to 
column, in order to inhibit serine proteases [94]. Further details of the protocol are outlined in 
Appendix 13.  
Figure 2.3 A simplified schematic of the affinity chromatography. Steps are as follows: 1) The sample, 
containing desired protein amongst various other proteins, is loaded onto column.  2) The polyhistidine-
tagged protein binds to the resin with high affinity, whereas other proteins flow through resin and column. 
3) Non-specific proteins are washed off, leaving only the proteins binding to the resin with higher affinity 
than to the wash solution. 4) Finally, the polyhistidine-tagged protein is eluted from the column with a 
solution that transcends the affinity of the protein to the resin. 
 
Optimization 
Although this affinity chromatography method has been utilised previously in our lab with 
success, it has been previously reported that occasionally, with engineered mutations, the 
stability and purity of these proteins are affected. Therefore, several optimization strategies 
where employed, specifically with the low expressing mutants, K98R and K98A, in order to 1) 
improve the percentage purity in the eluted protein, without having drastic effects on protein 
yield, and 2) to possibly improve the stability of protein samples.  Each one of these strategies 
was performed separately, in order to determine which is the most feasible.  
 
Alternative Buffer Composition 
The manufacturing company of the resin provide alternatives to the sonication buffer.  It is 
possible to add imidazole to the sonication buffer in a concentration of between 5 – 10 mM.  
The rationale is that by having a competing element within the sonication buffer, it is easier to 
prevent non-specific binding, as these by-products usually bind with low affinity to the column. 
Another alternative is to reduce pH of the wash buffer to 6.8, which is suggested to promote 
the removal of contaminants [92,93]. 
  
1) Load Sample 2) Binding 3) Wash 4) Elute 
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Protease Inhibitors 
A variation of protease inhibitors was used to test whether this could improve the purification 
results and prevent protein degradation (as in the case of the unstable mutant proteins). 
However, both the reducing agent, Dithiothreitol (DTT) and the metalloprotease inhibitor, Ethyl-
enediaminetetra-acetic acid (EDTA) often used in these protease inhibitor cocktails, are 
incompatible with the metal affinity resin.  Therefore, we made up a cocktail containing 7.2 mM 
Benzamidine, 5.0 mM N-Ethylmaleimide (NEM), and 4.2 mM PMSF. 
 
Cold Room 
Previous work in our lab with PPOX mutants were performed in the cold room at 4°C, which 
improved protein purity and also prevented immediate protein precipitation [94].  
 
Concentration & Glycerol 
It was also suggested in the Clontech Laboratories manual, as well as in other studies, that 
lower protein concentration would reduce the degree of protein precipitation. Between 10-20% 
sterile glycerol was also added to freshly purified mutant protein solution in order to prevent 
protein precipitation [95]. 
 
Assessment of Purity and Size of wild type and mutant PBGD 
Following purification, the protein samples were loaded on a 7.5 – 17.5% gradient SDS-PAGE 
gel (Appendix 14) in order to determine if the protein eluted is of the correct size and to assess 
purity at each step of the purification.  The optimization strategies were also verified using 
these SDS-PAGE gels. 
 
Protein Quantification 
The collected protein samples, including the load, void, wash and purified eluted protein, were 
quantified using the BioRad® (Bio-Rad® Laboratories Ltd, Johannesburg) micro-assay for 
protein quantification (Appendix 16). A standard curve was set up using a bovine serum 
albumin (BSA) sample range of known concentrations, and the concentration of samples 
extrapolated from the curve based on their absorbance at 595 nm. 
 
PBGD Activity Assay 
The activity of wild type and mutant PBGD was assessed by measuring formation of 
uroporphyrin I from porphobilinogen (substrate). Although PBGD catalyses the formation of 
hydroxymethylbilane (HMB) (Figure 1.5), the produced HMB can be converted non-
enzymatically to uroporphyrinogen I (Figure 2.4), which can be converted to uroporphyrin I by 
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spontaneous oxidation in the presence of ultraviolet light [9].  Uroporphyrinogen I, unlike 
uroporphyrinogen III, does not re-enter the mitochondrion as part of haem biosynthesis, and 
in this assay conditions are unfavourable for any downstream further processing of the 
uroporphyrin I. The production of uroporphyrin I is thus considered an accurate reflection of 
the production of HMB by the PBGD enzyme, as illustrated by Figure 2.5. BSA, of equivalent 
enzyme concentration, was used as a negative control. The protocol for this PBGD assay is 
detailed in Appendix 17.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.4 Illustration of the possible conversions of HMB (ChEBI_16645; or preurorphyrinogen), as 
adapted from [96]. Figure description as follows: (1) The conversion to uroporphyrin I (ChEBI_27484) 
non-enzymatically.  (2) The conversion to uroporphyrin III (ChEBI_15436) via uroporphyrinogen 
synthase [9]. Image was generated by ChemSketch Version 2.0 [5]. 
 
 
Figure 2.5 The reaction catalysed by porphobilinogen deaminase (PBGD) leads to the formation of 
HMB, that may be converted to uroporphyrinogen I non-enzymatically, as adapted from [9]. 
HMB 
Uroporphyrin I 
Uroporphyrin III 
(1) 
(2) 
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Kinetic Characterisation 
In order to determine the extent to which the engineered mutants effect PBGD’s kinetic 
function, the kinetic parameters, namely the substrate affinity (also Michaelis constant) (KM), 
and the maximal velocity (Vmax) were determined and compared to that of wild type enzyme. 
Data was fitted for a Michaelis-Menten kinetic curve using iterative curve fitting, done by 
GraphPad Prism, Version 6.03, for Windows (GraphPad Software, California, USA) using a 
least of square fit with a maximum of 1000 iterations. In the assay, increasing amounts of PBG 
(substrate) were used to a level of substrate excess. Thereafter, the enzyme turn-over rate kcat 
as well as the efficiency of the enzyme, expressed as the ratio of kcat/KM was determined 
(Appendix 18). 
 
Native PAGE Analysis 
Principle 
As a result of the step-wise polymerization of the PBG substrate by the enzyme, it has 
previously been demonstrated that it is possible to view differences in enzyme complex states, 
namely ES, ES2, ES3 and ES4, each corresponding to the number of PBG molecules being 
added onto the formation of the pyrrole ring on a non-denaturing 10% PAGE gel [48,85,97].  
The high concentration of acrylamide allows for the separation of the different complexes 
(Figure 1.11).   
 
Procedure 
The protocol for Native PAGE is similar to that of SDS-PAGE gels, except that the gel was a 
10% acrylamide gel not a gradient gel, and the denaturing/reducing agents SDS and β-
mercaptoethanol were not included in the sample loading dye.  Protein samples were run on 
a small Bio-Rad Gel electrophoresis system (courtesy of UCT Department of Surgery’s 
Research Lab), not the older systems used for SDS-PAGE gels routinely in our Porphyria Lab. 
The methodology was based on recently published work, and the protocol for the Native PAGE 
gel was kindly sent from Ms Helene Bustad, following personal correspondence [98].  Further 
details of the protocol is described in Appendix 25. 
 
DPM Co-Factor Analysis  
The co-factor assay is based on the unique reaction of the DPM co-factor with Ehrlich’s 
reagent, which consequently results in the tautomerisation of the dipyrromethane to a 
pyrromethane [58,84]. This may be tested chemically by the observation of a change in 
absorbance spectra over a time period [79,80]. Thereby, in order to test for the presence of 
the DPM co-factor, equal volumes of 0.5mg/ml of purified wild type, K98E or K98R mutant 
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PBGD, and a modified Ehrlich’s aldehyde were incubated in a 96 well plate, at room 
temperature. A spectral scan ranging from 440 – 650 nm was immediately performed and 
repeated after a 20-minute interval. The scan was examined for a spectral shift (see Appendix 
19 for details). 
 
DPM Co-Factor Removal  
This methodology is based on the work of Hart et al. 1988 [80].  The aim of this was to remove 
the bound DPM co-factor from wild type PBGD, and following this to reconstitute the enzyme 
activity by the addition of the substrate (PBG), or, additionally in our case, the DPM co-factor 
itself.  
Procedure 
In brief, wild type protein was subjected to hydrolysis with concentrated HCl (1M) in order to 
cleave the DPM from the bound Cysteine 261 residue (Figure 1.7) [67]. Following 25-hour 
incubation in the dark at room temperature, protein was refolded using a series of dialysis 
steps.  Finally, the ‘apo’ protein, lacking the DPM co-factor was concentrated and kept at 4°C. 
The detailed protocol is outline in Appendix 20. 
 
PBGD reconstitution assay 
Principle 
This protocol is based on the principle of Hart et al. (1998) whereby PBG was added to the 
generated ‘apo’ PBGD enzyme in order to ‘rescue’ and attempt to restore activity[80]. For our 
interest, we wanted to test whether we could repeat this method, and, if so, if it was possible 
to test whether the ‘apo’ - enzyme would accept, and show preference for its DPM co-factor 
versus the PBG substrate [84].  The rationale for this is further detailed in the discussion and 
not outlined here.   
Procedure 
The assay is based on our previously detailed assay for PBGD activity.  The methodology was 
slightly altered in order to incorporate testing of the DPM co-factor, either independently or in 
combination with the substrate.  Details for this assay are outlined in Appendix 21. 
 
DPM Solubility 
The DPM co-factor is commercially available and was purchased from Frontier Scientific (USA 
address and then represented by Labretoria in South Africa).  However, very little information 
is available regarding its solubility in organic solvents other than methanol.  We therefore had 
to determine whether the DPM cofactor was soluble in solutions comprised of different 
percentages of 1M imidazole and methanol (results shown in Chapter 3). 
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Circular Dichroism Analysis 
The PBGD wild type and mutant enzymes were subjected to circular dichroism studies in order 
to investigate possible changes in protein secondary structure, and conformational stability as 
a result of the different mutations.  This work was undertaken at the Central Analytical Facility 
(CAF) at Stellenbosch University, under the guidance of Dr. Jaco Brand (CAF) and mentoring 
from Professor Marina Rautenbach (Department of Biochemistry). 
 
Principle 
Circular Dichroism is based on the principle of polarised light and the differences in absorption 
of optically active (chiral) molecules within a chemical bond, peptide as well as proteins [99].  
As shown in Figure 2.6 polarised light is light that travels in a single direction.  
 
With circular dichroism, light is circularly polarised, allowing for either the rotation of light in a 
clock- or counter-clock wise direction [99].  When asymmetric molecules, like proteins, interact 
with this circularly polarised light, they may absorb the right- and left-handed light a different 
extent, as shown in Figure 2.7 [99,100].  
Figure 2.6 A simplified illustration of different polarised light.  Each light beam has been polarised to 
allow only for the transmission of light in the indicated direction (by arrows). 
 
Procedure 
The methodology for the far-UV analysis of the wild type and mutant PBGD enzymes is based 
on the work done by Bustad et al. (2013) [98], except our work was performed on a Chirascan 
Plus CD Spectrophotometer (Applied Photophysics Limited, United Kingdom) 
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Figure 2.7 An illustration of the origin of the CD effect. 1. Figure descriptions as follows: (A) Circularly 
polarised light components, left (L), and right (R). Seen in (I), When the L & R components have the 
same amplitude, it generates plane polarised radiation when combined.  (II) If however, the components 
have different magnitudes, the subsequent light is elliptically polarized (dashed line). (B) Illustration of 
the relationship between ellipticity and absorbance. Band 1 has no CD spectrum, due to an achiral 
chromophore; Band 2 has a positive CD spectrum with L absorbed more than R; Band 3 has a negative 
CD spectrum, as more R is absorbed than L [99].	  
 
Freshly purified protein sample was exchanged to a new buffer (CD Buffer) which is not 
optically active with the use of PD-10 desalting columns [100]. Details for the buffer exchange 
are discussed in Appendix 22.  Protein was then diluted to a final concentration of 7µM.  Scans 
were set up in a range of 190 – 300 nm, with the temperature controlled at 25°C by a far-UV 
analysis was done in the range of 190 – 260 nm, to measure the secondary (α-helical and β-
sheet) content of wild type and mutants. The near-UV analysis (260 – 300 nm) was done to 
measure the ‘tertiary footprint’ of the protein, by the presence of the aromatic rings, 
phenylalanine, tyrosine and tryptophan peaks at between 255 – 270 nm, 275 – 282 nm, and 
290 nm respectively [99].  Protocol further detailed in Appendix 23. 
 
Data Fitting and Analysis 
 
CDPro 
Data was corrected for the buffer (blank) and normalized to the final five readings (295 – 
300nm) in order to have a more accurate representation of the circular dichroism data.  The 
normalization of the data allowed for adjustment of the scale without affecting the meaning of 
the dataset. Data was further normalized by calculating the mean residue ellipticity ([θ]MRW), 
according to the following formula illustrated below (Figure 2.8) [99].  This ensures the data for 
each sample is independent of the protein residue composition [101]. 
  
A B 
I II 
1 2 3 
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[θ]MRW = (106  x  θ) / c  x  l  x n 
Figure 2.8 The formula for the conversion of ellipticity (θ) in millidegrees (mdeg) to mean residue 
ellipticity [θ]MRW where c is the concentration of the protein in µM, (l) the path length in millimetres (mm), 
and (n) the number of residues in the protein (361 for non-erythroid).The multiplication with 106 allows 
for final answer expressed in (deg.cm2.dmol−1residue-1).	  
 
Data was analysed using CDPro, by the CONTINLL [102,103], SELCON3 [104,105] and 
CDSstr algorithms [106]. The CDPro software, however, is only able to estimate secondary 
structures within the range of 190nm to 240 nm, as well as data in molar circular dichroism 
(Δε).  The conversion from mean residue ellipticity ([θ]MRW) is shown below in Figure 2.9.   
 
 Δε = [θ]MRW / 3298 
Figure 2.9 The relationship of molar circular dichroism and the mean residue ellipticity [θ]MRW as noted 
from [99].	  
 
Ten reference sets were screened against each sample and the secondary protein estimation 
calculated from the mean of the top 5 reference set for each algorithm.  The more converged 
the results are, the higher the confidence in the protein estimation of secondary structure [107]. 
One-Way ANOVA statistical tests were performed from the mean of the final result of the three 
different algorithms (CDStr, CONTINLL and SELCON3), in order to test if changes amongst 
mutants were significant in comparison to wild type. 
 
This methodology for data analysis and choice of CDPro algorithms is based on the work of 
Professor Marina Rautenbach (SU), with whom this work was done. A more detailed 
description of the different algorithms can be found on the Dichroweb website 
[http://dichroweb.cryst.bbk.ac.uk/html/references.shtml]. 
 
CDNN 
The CDNN algorithm is another software used for the estimation of the protein secondary 
structure.  Although it is not as robust as the CDPro, it does allow for a graphical comparison 
of the wild type to different mutants, as it includes random coils and β-turns [108].  
 
Thermal Denaturation Profiles 
Procedure 
The methodology for the thermal analysis of the wild type and mutant PBGD enzymes is also 
based on the work done by Bustad et al. (2013) [98]. Protein samples were prepared similarly 
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to the far-UV scans (Appendix 23). The ellipticity was recorded at 208 nm and 222 nm as a 
function of temperature between 20 and 90°C.  Stepped temperature ramping was allowed for 
a total of 300 seconds at each temperature point – this was done in order to allow for the 
cuvette to reach as close to the desired ‘set’ temperature.  Independently purified samples 
were repeated twice, with adaptive sampling on the Chirascan Software (Applied Photophysics 
Limited, United Kingdom). Detailed protocol further discussed in Appendix 24. 
 
Data Fitting and Analysis 
Data from the thermal spectrums were fitted to this a two-state unfolding model as detailed in 
Figure 2.10.  During a two-state unfolding of a protein, there are only two species present in 
considerable amounts, namely the folded (or native) protein (N) and the unfolded protein (U).  
Therefore, the following is true for the total account of folded and unfolded protein: 
 
 fN  + fU  = 1 (1) 
 
So, it may be deduced that, at any point during the transition from native to unfolded protein, 
the observed signal is as follows: 
 θt = θNfN + θUfU (2) 
 
By rearranging this equation (2), the fraction of folded protein may be expressed as follows: 
 
 fN = (θt – θU) / (θN – θu) (3) 
 
Figure 2.10 The derivation of the fraction of unfolded protein, as determined from the circular 
dichroism data from thermal curves, as described previously.  (1) The fraction of protein species, where 
the sum of native (folded) protein (fN), and unfolded protein (fU) are equal to 1.  (2) The representation 
that the measured/observed ellipticity (θ) at any given point (i.e. each temperature point) is the sum of 
the fraction of native protein and unfolded protein.  (3) The final equation for the fraction of folded protein. 
 
 
The use of equation 3 allowed for the conversion of data, as presented in millidegrees, to be 
converted to fraction of folded protein for each respective temperature point. Results were 
plotted in GraphPad Prism Version 6.02 for Windows, expressed in millidegrees [98,109,110]. 
Our interest was not to further investigate the thermodynamic principles of the protein folding 
and refolding; hence we did not further extrapolate van Hoff’s formula for free energy (ΔG).  
The melting Temperatures (Tm) for wild type and each mutant was determined from the fitted 
data at 222 nm, that was plotted on a non-linear regression, and fitted to the Levenberg–
Marquardt algorithm using the Origin Pro Software (OriginLab, Northampton, MA) [110].  
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Protein Structural Analysis 
As highlighted in Chapter 1, several crystal structures have been published for the PBGD 
enzyme (Table 1.1).  The most characterised to date is the structures in E.coli. However, we 
preferred to work with the human enzyme, as we were expressing two clinical human 
mutations.   
 
The two crystal structures available for the human enzyme both lack several loop regions, 
including the active site loop as mentioned previously [60,67].  However, it is possible to 
perform homology studies amongst the different crystal structures, and thereby have a 
modelled enzyme, based on the human form, with the ‘missing loops’ modelled from other 
crystal structures. The online bioinformatics tool and database, Expasy, hosts a range of 
homology systems that provides an online interface for homology predictions [111].   
 
We utilised CPH models Server 3.0 as is suggested for protein homology [112].  The sequence 
from the Protein Data Bank (PDB) file from the 3ECR crystal was used, as this crystal structure 
did not contain a mutation, like the 3EQ1 [60,67].  The CPH Server can access all the data of 
known published crystal structures for the sequence that it recognises.  Thereby, the active 
site loop could be ‘modelled’ from the crystal in the higher plant species Aradopsis thaliana 
[68]. In addition, it is possible to submit the protein sequence with the desired mutation prior to 
the homology modelling.  This allowed for the incorporation of the mutation into the homology 
modelling, instead of just altering the amino acid manually.   
 
The final modelled structure(s) (wild type and mutants), based on the human enzyme form 
(3ECR), were minimised with 150 steps of steepest decent, followed by 100 steps conjugated 
descent in order to allow for lowest energy configuration.  The molecular graphics and analyses 
were performed with the UCSF Chimera package. Chimera was developed by the Resource 
for Biocomputing, Visualization, and Informatics at the University of California, San Francisco 
(supported by NIGMS P41-GM103311) [61].   
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Introduction 
This chapter details all of the relevant results obtained for this dissertation.  It follows the same 
order as that described in Chapter 2 for the methodology.   
 
Site-Directed Mutagenesis 
To assess the contribution of PBGD active site residues towards the enzyme’s activity and co-
factor interaction, single amino acid conversions (K98E, K98R and K98A) were introduced and 
the mutants expressed in JM109 supercompetent E.coli cells using the QuickChange® 
methodology.  
 
Screening of the entire HMBS gene (sequence given in Appendix 2) revealed that no additional 
mutations had been introduced (data not shown). Following validation that each engineered 
sample was a true representation of the desired mutation, we pursued the expression, 
purification and characterisation of each mutant protein product, in terms of kinetics, co-factor 
interaction as well as structural analysis. 
 
Restriction Analysis to confirm K98R sequence 
The K98R mutant allowed for a restriction analysis of a new identified restriction enzyme site 
by Bsm FI and showed successful mutation for all eight colonies screened (Table 3.1 and 
Figure 3.1). An additional cutting site was generated, indicated by the presence of bands at 
114bp and 258bp. 
 
Table 3.1 Bsm FI restriction analysis for screening of the K98R. 
Mutation 
Size 
(bp) 
Restriction 
Endonuclease 
Recognition 
Sequence 
Digest Products (bp) 
Wild Type Mutant 
K98R 677 Bsm FI 5’-GGGAC(N)10-3’ 305; 372 114; 258; 305 
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Figure 3.1 The Bsm FI restriction digest of the K98R mutation. Lanes are labelled as follows: M) 
Molecular Marker (U) Uncut PCR product (W) Wild type PBGD; (1- 8) Selected K98R colonies. 
 
Confirmation of Mutated Sequences 
Direct sequencing showed successful engineering of the mutants. Figure 3.2 shows a partial 
direct sequencing for each mutant and Table 3.2 outlines the nucleotide change(s) in each 
respective mutant. As noted in Chapter 2, samples were sequenced in both the forward and 
reverse direction, in order to 1) confirm the mutation at the right position, and 2) to observe 
that no additional mutations were introduced.  Samples were compared to the Genbank 
sequence for human HMBS, as noted in Appendix 1. 
 
For the K98A mutation, two base pairs were altered from the wild type lysine (AAG), to GCG 
for alanine. As detailed in Appendix 9, the PCR for the mutagenesis was adapted slightly in 
order to increase the cycle time from 12 cycles to 16 cycles, as suggested by the 
QuickChange® protocol. 
 
Table 3.2 The base-pairs of residue lysine 98 of the PBGD enzyme, illustrating the respective 
nucleotide change(s) in each mutation. 
 Wild Type K98E K98R K98A 
Residue 98 AAG GAG AGG GCG 
  
500 
400 
300 
200 
100 
700 
(bp) M    U   W   1     2    3     4    5     6    7    8 
677bp 
372bp 
114bp 
305bp 
258bp 
   42 
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Figure 3.2 Partial direct sequencing of the K98E, K98R and K98A mutants using a forward primer. 
The wild type sequence is shown above the mutant read sequence.  The base pair change(s) is identified 
by an arrow and the underlined nucleotides signify the 98 residue.  (I) K98E mutation showing the base 
change from AAG to GAG  (II) The K98R mutation showing the base change from AAG to AGG and (III) 
The K98A showing the base changes from AAG to GCG. 
 
I 
II 
III 
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Expression and Purification of PBGD 
The successfully expressed wild type and mutant proteins were subsequently purified using 
TALON™ metal affinity chromatography, as described in detail in Chapter 2. Previous work in 
our laboratory on PPOX in the same expression system showed that IPTG did not significantly 
improve protein expression, and the PBGD expression levels we obtained without IPTG 
induction were adequate for the intended purpose [94,113]. Table 3.3 illustrates the purification 
table for the PBGD wild type and mutant enzymes. The K98E had very high expression levels 
compared to the others. However, the activity of the eluted protein was still significantly lower 
in comparison to wild type.   
 
Table 3.3 A representative purification table combining the data obtained in a number of protein runs 
of the wild type and mutant PBGDs showing protein yield, activity and percentage recovery. 
 Volume (ml) 
[Protein] 
(µg/ml) 
Total 
Protein (µg) 
Specific 
Activity 
(pmol/µg/h) 
Total 
Activity 
pmol/h 
Recovery 
(%) 
WT       
Load 25 14.7 368 26 9568 100 
Void 23 13.2 304 2.5 760 8.0 
Wash 10 0.6 6.0 24 144 1.5 
Eluate 1.5 6.0 9.0 555 4995 52 
K98E       
Load 30 14.4 432 94 40608 100 
Void 30 12.7 381 1.7 648 1.6 
Wash 11 0.7 7.7 40 308 0.8 
Eluate 1.4 17.7 25 297 7425 18 
K98R       
Load 30 9.6 288 4.2 1210 100 
Void 28 8.9 249 2.5 623 50 
Wash 11 0.4 4.4 0.3 1.3 0.1 
Eluate 1.5 3.4 5.1 0.5 2.6 0.2 
K98A       
Load 28 6.2 174 1.2 209 100 
Void 25 6.5 163 0.7 114 55 
Wash 10 0.2 2.0 0.2 0.4 0.2 
Eluate 1.5 4.3 6.5 0.6 3.9 1.9 
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Table 3.4 shows just the specific activities of the pure eluted proteins, providing a comparison 
of the mutants to wild type, expressed as a relative percentage to the wild type PBGD, which 
was normalized to 100%. 
 
Table 3.4 The specific activities for the wild type, K98E, K98R and K98A and the relative specific 
activity (expressed as pmol/µg/h) and the fraction (shown as %) to wild type specific activity. 
 Specific Activity 
 pmol/µg/h Relative to Wild Type (%) 
Wild Type 555 100 
K98E 297 54 
K98R 0.5 0.1 
K98A 0.6 0.1 
 
To check the purity of the protein and confirm the correct size of eluted protein, specifically 44 
kDa for the non-erythroid form, a gradient SDS-PAGE was performed for each sample as 
illustrated in Figure 3.3. The images presented are illustrative of the degree and nature of 
purifications achieved for each expressed mutant. 
 
A useful feature of any form of PBGD that has its DPM co-factor bound is that it exhibits a 
characteristic pink colour (see Chapter 1, Figure 1.8). This feature was utilised in monitoring 
our PBGD purification. However, for the K98R and the K98A mutants, several fractions of 
eluted protein had to be collected in the region of expected elution, since the protein had no 
characteristic pink colour (as in wild type and K98E). These additional fractions were loaded 
onto the gel in order to deduce which fraction contained the purified PBGD protein. Following 
confirmation of correct protein size and purity on the SDS-PAGE as well as the Bradford 
Protein Assay (as described in Chapter 2), the eluted protein samples of adequate 
concentration were pooled and concentration of pooled sample determined. 
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Figure 3.3    The 7.5 – 17.5% gradient SDS-PAGE of wild type and mutant PBGD. Lanes are labelled 
as follows: (M) Rainbow Marker, (L) Load, (V) Void, and (W) Wash.  With regards to the eluted 
proteins – Wild type: (1-3) Purified eluted protein. K98E: (1&2) Purified protein, and for K98R several 
fractions were collected (1-6), of which the first fraction (1) contained no protein. 
 Wild Type 
        K98E 
  K98R 
97.4 
30 
14.5 
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Optimization of Mutant Expression  
Initial purification of the K98A revealed issues pertaining to the stability of the protein as well 
as to the high level of non-specific proteins that were binding to the TALON™ resin and thus 
eluting with the protein of interest (Figure 3.4). 
 
In order to address these issues several alternatives were attempted (as detailed in Chapter 
2), finally reaching a satisfactory pure protein by adding a total of 10 mM imidazole in the 
sonication (1st buffer) (Figure 3.5), reducing the resin volume used to 1 ml, and performing the 
entire purification at 4°C (Figure 3.6).  
 
Figure 3.4 The initial 7.5 – 17.5% gradient SDS-PAGE of the K98A mutant PBGD protein. Lanes are 
labelled as follows:  (M) Rainbow Marker  (L) Load  (V) Void  (W) Wash (1-6) eluted fractions. Arrows 
highlighted in red illustrate some of the contaminants that co-eluted with the K98A protein of interest. 
 
As illustrated in Figure 3.5, the addition of the 5 mM imidazole together with the reduction of 
resin volume of 1.2 ml enabled us to eliminate a proportion of the non-specific proteins whilst 
at the same time maintaining the yield of desired protein. However, this strategy did not 
eliminate all of the non-specific protein fractions. 
 
We then further optimised the protocol for purification of the K98A mutant protein, which 
included the reduction of the TALON™ resin to 1.0 ml, a total of 10 mM imidazole added to the 
sonication buffer, as well as the purification performed at 4°C (Figure 3.6). Although this slightly 
affected protein yield, the total protein obtained was still satisfactory to perform downstream 
assays and characterisation.  Although we had several other optimization strategies including 
alterations of the wash buffer (as discussed in Chapter 2), these strategies proved 
unsuccessful and are not shown. 
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Figure 3.5 The 7.5 – 17.5% gradient SDS-PAGE of the K98A mutant PBGD protein of the purification 
done with the reduced TALON™ resin volume of 1.2 ml together with the 5 mM imidazole in the 
sonication buffer. Lanes are labelled as follows: (M) Rainbow Marker (L) Load (V) Void (W) Wash (1-6) 
eluted fractions. Arrows highlighted in red illustrate some of the contaminants that co-eluted with our 
K98A protein of interest. 
 
 
Figure 3.6 The 7.5 – 17.5% gradient SDS-PAGE of the K98A mutant PBGD protein of the purification 
done with the further reduced TALON™ resin volume of 1.0 ml together with the 10 mM imidazole in the 
sonication buffer. Lanes are labelled as follows: (M) Rainbow Marker (L) Load (V) Void and (W) Wash 
and (1-6) eluted fractions. 
 
 
With regards to the impurities for the K98R and K98E mutants, the yield for the K98E of the 
desired protein was satisfactory and the comparison of the concentration of the PBGD versus 
the impurities was very low, hence the protein was considered of adequate purity. With regards 
to the K98R, the same optimization strategy as was done for the K98A was performed, and it 
was found that the protein purity could be improved to some extent, as shown in Figure 3.7 
below. 
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Figure 3.7 The 7.5 – 17.5% gradient SDS-PAGE of the K98R mutant PBGD protein of the purification 
done with the further reduced TALON™ resin volume of 1.0 ml together with the 10 mM imidazole in the 
sonication buffer. Lanes are labelled as follows:  (M) Rainbow Marker  (L) Load  (W) Wash (1-2) eluted 
fractions. 
 
The protein yield for the K98R was still very low, although we still had an adequate amount of 
protein to perform all assays. In Figure 3.7, only two protein fractions were loaded, as the 
samples were pooled prior to the running of the gel. In all of the optimization strategies, 
although the protein purity was increased, the protein stability remained problematic, even 
when purifications were performed at 4°C.   
97.4 
30 
(kDa) 
   M       L      W      1        2    
3 
14.5 
21.5 
44 kDa 
46 
200 
   49 
 
Kinetic Characterisation 
Figure 3.8 below shows comparative illustrative kinetic substrate-velocity plots for the wild 
type, K98E and K98R generated using GraphPad Prism, Version 6.01. 
 
Figure 3.8 The Michaelis-Menten, substrate-velocity plots for the wild type, K98E and K98R mutants 
following the 20-minute kinetic assay. Activity is expressed as the number of picomoles of Uroporphyrin 
I produced per nanogram of PBGD added per hour [pmol/ng/h].  
  
Wild Type 
K98E 
K98R 
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Table 3.5 illustrates the kinetic parameters calculated for the wild type, K98E, K98R and K98A 
from the substrate-velocity data. The results represent the mean from three independent 
assays using purified protein.  The kinetic characterisation of the K98A mutant proved to be 
difficult. The extremely low/negligible activity of this mutant (Table 3.5; Figure 3.9) resulted in 
small variations in fluorescence readings correlating to severe scattering of kinetic plots and 
no stable reading was recorded, results ranging from 0.5 to 500 µM. Several alternatives were 
attempted including an increased incubation time, increases and decreases of enzyme 
concentration, to no avail. A graphical output of Table 3.5 is presented in Figure 3.9 below. 
 
Table 3.5 The kinetic constants for the engineered K98A PBGD enzyme in relation to the previously 
analysed wild type and other mutant PBGD enzymes.  Standard error is expressed as standard error of 
the mean (SEM). 
 KM (µM) Vmax (pmol/ng/hour) kcat (s-1) 
kcat /KM  
(µM-1.s-1) 
Vmax % of WT 
Wild Type 8.49 ± 0.136 1.71 ± 0.299 51.3 ± 8.95 6.04 100 
K98E 30.7 ± 2.97 1.06 ± 0.072 31.7 ± 2.17 1.03 62.00 
K98R 5.69 ± 0.812 0.029 ± 0.002 0.878 ± 0.06 0.15 1.70 
K98A - 0.026 ± 0.005 0.184 ± 0.03 - 1.52 
 
 
The results for the kinetic constants for wild type and mutants, as shown in Table 3.5, are 
(where necessary) expressed to three significant figures.  We did this as it was difficult to 
express the data to a two decimal notation with the low levels of activity for the K98R and K98A 
mutants.  From Figure 3.9 it may be noted that the substrate affinity for the K98E mutant 
illustrated an approximate three-fold increase in comparison to wild type, suggesting a 
significant reduction in the substrate affinity of this mutant. The K98R had a comparable KM to 
that of wild type (Figure 3.9).    
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Figure 3.9 A graphical illustration, comparing the kinetic constants as determined in Table 3.5.  I) 
Illustrates the comparative substrate affinity (KM) of each sample. II) The maximum velocity achieved for 
each sample (Vmax). III) The catalytic efficiency of each respective sample, as indicated by the (kcat /KM) 
ratio. IV) The Vmax for each sample expressed as a percentage of wild type (%WT). 
IV 
II 
III 
I 
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Native PAGE Analysis 
Native PAGE gels were run in order to observe if the enzyme-substrate complex profiles for 
each mutant was different to that of wild-type. In addition, it was interesting to see whether any 
observed differences could be correlated to the mutants’ kinetic results.  
 
The different bands on the gel for wild type PBGD illustrate the different enzyme substrate 
complexes, as discussed in Chapter 1, Figure 1.11.  However, following several optimization 
strategies and attempts, it appeared that none of the mutant proteins were stable enough to 
observe the enzyme complexes, as could be observed in the wild type, illustrated in Figure 
3.10. 
 
 
Figure 3.10 The 10% native PAGE for wild type PBGD and each of the mutants.  The different bands 
indicated in the wild type enzyme are described as followed: ES – enzyme with one PBG; ES2 – enzyme 
with 2 PBGs; ES3 – enzyme with 3 PBGs; ES4 – enzyme with 4 PBGs. The (*) indicated in the K98E 
represents a band on the gel observed migrating higher than the ES band. 
 
The band that appears higher on the gel in the K98E mutant (indicated by the *), has been 
previously suggested in the literature to be the partially folded holoenzyme. This might suggest 
why K98E, although still able to bind the co-factor, still appeared unstable and shows structural 
defects, which is further discussed in Chapter 4. 
  
ES1 
ES2 
ES3 
ES4 
K98E K98R K98A WT WT WT 
* 
   53 
 
DPM Co-Factor Analysis 
The aim of this assay was to investigate the effect of the active site mutations on the enzyme’s 
ability to bind its DPM co-factor. Figure 3.11 shows the spectral scan (450 – 650nm) for the 
wild type, K98E, K98R and K98A mutants. Both the wild type and K98E mutant PBGD illustrate 
the characteristic spectral shift from 564 nm to 495 nm over a 20-minute time period thus 
confirming the ability of the wild-type and K98E PBGD mutant to bind the co-factor. In contrast 
the absence of a spectral shift for the K98R and K98A mutants confirmed the loss of cofactor 
binding (which we had speculated due to the loss of characteristic ‘pink’ colour during 
purification). 
 
 
 
 
 
 
 
Figure 3.11 Spectral features of PBGD wild type and mutant proteins. Co-factor analysis showing the 
spectral shift from 564 nm to 495 nm following 20-minute incubation.  The graphs are indicated as time 
zero T0 indicated by the solid line, whereas time T20 is indicated by the (- - - - -) dotted line [80]. Graphs 
and images generated by GraphPad Prism, Version 6.01. 
  
Wild Type K98E 
K98R K98A 
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DPM Co-Factor Removal 
In order to prepare the ‘apo’ enzyme for the planned reconstitution assays to study DPM 
binding characteristics, wild type protein was hydrolysed with HCl in order to cleave the DPM 
from the enzyme (as discussed in Chapter 2). As shown in Figure 3.12, the DPM co-factor was 
successfully removed from the native wild type PBGD. This was proven by the negative 
reaction of the sample with the Ehrlich’s reagent and no spectral shift was observed, thus 
behaving similarly to the K98R and K98A (as shown in Figure 3.11).  
 
 
Figure 3.12 Spectral features of PBGD wild type and the ‘apo’ enzyme. Co-factor analysis showing 
the spectral shift from 564 nm to 495 nm following 20-minute incubation.  The graphs are indicated as 
time zero T0 indicated by the solid line, whereas time T20 is indicated by the (- - - - -) dotted line [80]. 
Graphs and images generated by GraphPad Prism, Version 6.01. 
 
Although we were able to successfully remove the co-factor, there were several difficulties with 
this protocol, including the stability of the protein for assays, which is discussed in detail in 
Chapter 4. 
 
PBGD Reconstitution assay 
 
DPM Solubility 
In order to test the solubility of the DPM co-factor, 5 mM of DPM (in powder form, as purchased) 
was added to different ratios of methanol and imidazole. All samples were tested, and kept at 
4°C overnight, to observe whether the samples would remain soluble, or precipitate. Imidazole 
was chosen as the solvent due to the similarity of the amine to that of the DPM co-factor 
(Chapter 1; Figure 1.8).   
 
As illustrated in Table 3.6, the DPM was soluble in 50% v/v methanol and imidazole.  Further 
reductions in methanol resulted in precipitation of the co-factor overnight. We therefore chose 
to use the 50% v/v solvent. With regards to the effect the methanol on protein, we tested 50% 
methanol with 0.1 mg/ml and 1 mg/ml concentrations of BSA, and found that it had no effect 
on the protein, and no precipitation of protein occurred. 
Wild Type ‘apo’ enzyme 
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Table 3.6 The range of solutions of imidazole and methanol in which the DPM co-factor solubility was 
tested. 
 
Assay 
Table 3.7 illustrates the results for the reconstitution assay following the addition of either the 
PBG substrate or the combination of substrate with the DPM co-factor.  This assay was based 
on the original assay we used for the PBGD activity (Chapter 2; Appendix 21).  The maximum 
activity we were able to achieve following reconstitution was approximately 22% of the wild 
type.   
Several alternatives and troubleshooting mechanisms were adopted in order to attempt a 
better ‘recovery’ of the enzyme following re-addition of the native enzyme substrate (and or 
co-factor), all of which did not significantly alter or improve our final results.  A detailed 
description of alternatives and the troubleshooting is described in Chapter 4. 
Table 3.7 The reconstitution of ‘apo’-enzyme with either substrate (PBG) only, or in combination with 
the DPM co-factor.  Assay was performed at 4°C as well as 37°C. 
 
  
100% methanol 
70% methanol; 
30% imidazole 
50% methanol; 
50% imidazole 
30% methanol; 
70% imidazole 
100% imidazole 
Soluble Soluble Soluble Precipitates O/N Not soluble 
 Enzyme 
Sample  
Vmax 
(pmol/ng/hr) 
Vmax 
% of WT 
37°C Wild Type 
Substrate 1.87 
- 
Substrate & Co Factor 1.87 
37°C ‘apo’-enzyme 
Substrate (4 hours) 0.4254 22,4 
Substrate & DPM Co-factor 0.4030 21,3 
4°C ‘apo’-enzyme 
Substrate (4 hours) 0.0683 3.45 
Substrate & DPM Co-factor 0.0598 3.02 
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Circular Dichroism Analysis 
Far-UV 
Figure 3.13 illustrates the spectrum obtained for each of our respective samples.  Each sample 
is represented as the mean of a minimum of 3 spectral scans that were prepared from 
independently purified protein samples. Data was normalized and converted to mean residue 
ellipticity as described in Chapter 2.  
Figure 3.13 Illustration of the comparative far-UV analysis of wild type and mutants.  Wild Type (green; 
n ), K98E (red; q ), K98R (blue; l ) and K98A (orange; Ï ).  Graphs were smoothed to a second order 
(polynomial) with a maximum of 4 neighbouring points and converted to mean residue ellipticity - [θ]MRW 
(deg.cm2.dmol-1residue-1). Graph images generated by GraphPad Prism, Version 6.01. 
 
Data Analysis 
The spectra analysis for protein secondary structure is within the range of 190 nm and 260 nm, 
with alpha helical proteins indicating negative peaks at 208 nm and 222 nm and a positive 
peak at 193 nm [100]. However, in order to ensure data collected was represented accurately 
in our graphic presentation, our spectra were collected between 190 nm to 300 nm.  The raw 
data, in millidegrees (mdeg), were then minimised from the CD buffer blank, and normalized, 
by subtracting the average of the final readings (295 – 300 nm,) prior to data conversion to be 
expressed in mean residue ellipticity as shown in Figure 2.9.  Important to note, is that this 
normalization does not in any way alter the results, but rather allows for the normalization of 
data points, resulting in a smoother curve, without the need to apply further smoothing 
techniques and exclusion of data points [108].  
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Each of the respective algorithms in the CDPro software has a maximum of 10 reference sets.  
For our samples we used reference sets SP37, SP43, SDP42, SDP48 and CLSTR.  Our 
selection of protein reference was on grounds of consistent structure prediction [106,107]. Data 
displayed is the mean of the best five fits for each algorithm and the error expressed as the 
standard error of the mean (SEM) (Table 3.8).  One-way ANOVA statistical tests revealed that 
the change in α-helical content of the K98E was significant (p<0.01) in comparison to the wild 
type.  Although the β-sheet content for the K98R was higher for CONTINLL and SELCON3, 
these differences were insignificant in comparison to wild type. 
Table 3.8 Secondary structure estimations performed with the CDPro software, using the CDSstr, 
CONTINLL and SELCON3 algorithms.   
 α-helix (%) β-sheet (%) 
 CDSstr CONTINLL SELCON3 CDSstr CONTINLL SELCON3 
WT 20.8 ± 0.10 22.1 ± 0.20 21.6 ± 0.29 25.9 ± 0.47 25.8 ± 1.14 26.4 ± 0.48 
K98E 16.7 ± 0.14 17.9 ± 0.35 17.8 ± 0.47 28.9 ± 0.47 29.9 ± 0.57 27.1 ± 1.7 
K98R 19.7 ± 0.19 20.2 ± 0.23 21.0 ± 0.64 25.4 ± 1.06 38.1 ± 0.71 35.6 ± 0.66 
K98A 20.3 ± 0.17 21.1 ± 0.19 21.6 ± 0.18 30.8 ± 0.37 28.3 ± 0.24 24.9 ± 0.09 
 
In order to further correlate our findings with known wild type data, we calculated the mean of 
the wild type estimation data from CDPro and compared it to the two previously published 
crystal structures of human PBGD available in the PDB database (PDB ID(s): 3ECR and 
3EQ1) [60,67].  We used two algorithms that are available via online servers, DSSP [114] and 
STRIDE [115,116].  These servers allow for the secondary structure prediction from crystal 
structure data coordinates. Data is outlined in Table 3.9 below. The 3EQ1 was not recognised 
in the STRIDE database, and therefore no estimations could be made. 
 
Table 3.9 Secondary structure estimations performed from the two human crystal structures (3ECR 
and 3EQ1) with the online secondary structure algorithms, DSSP and STRIDE.  
 WT 3ECR 3EQ1 
 DSSP STRIDE DSSP STRIDE 
α-helix (%) 21.5 28.7 30.0 32.0 - 
β-sheet (%) 26.0 19.8 20.1 21.9 - 
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Although the data obtained for the wild type enzyme is comparable with those of the published 
crystal structures, the ratio of α-helices and β- sheets is different.  However, this is most likely 
attributed to the fact that the wild type sample is a native soluble protein, whereas the crystal 
structures are ‘static’ representations of the enzyme. The final analysis for the far-UV data was 
to graphically illustrate all of the secondary structure predictions for the wild type and mutant 
proteins, as shown in Figure 3.14.  The CDPro software does not allow for the 
prediction/estimation of the random coils and differences between parallel and antiparallel β-
sheets [117].  The data is shown as percentage of the whole (100%), with the CDNN algorithm 
set to ‘advanced spectra’ in order to have the best and most accurate ‘fit’ of data estimation.  
The same data input that was used for each respective sample in the CDPro analysis was 
used for the CDNN estimation. 
Figure 3.14 Illustration of the comparative far-UV analysis of wild type and mutants done by the CDNN 
algorithm in order to show the collective estimation of all structures in each respective sample [108]. 
Graph images generated by GraphPad Prism, Version 6.01. 
Near-UV  
Figure 3.15 illustrates the near-UV spectra for each of the mutant samples (dotted lines) 
compared to wild type enzyme. Near-UV analysis is measured normally between 240 to 300 
nm and indicates the presence of aromatic rings – specifically phenylalanine (F), tyrosine (Y) 
and tryptophan (W) [99]. It is said to be the ‘tertiary footprint’ of the protein structure, in that the 
presence of these peaks may indicate a tertiary structure, and hence correct folding of a protein 
[98].  The aromatic rings have characteristic peaks namely: between 255 and 275 nm for 
phenylalanine, tyrosine a peak between 275 and 282 nm, and tryptophan from 290 nm [116]. 
Graphs were smoothed to a second order (polynomial) with a maximum of three neighbouring 
points and expressed in mean residue ellipticity [θ]MRW (deg.cm2.dmol-1residue-1). 
α-Helix
β-sheet
Parallel
β - Turn
Random Coil
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Figure 3.15 Comparative near-UV analysis of wild type and mutant PBGD. In the first graph of 
the K98E mutant, the peaks observed for phenylalanine (F) tyrosine (Y) and tryptophan (W) 
respectively are illustrated in the wild type spectra. Graph images generated by GraphPad Prism, 
Version 6.01. 
 
K98E 
K98R 
K98A 
F 
Y 
W 
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CD Thermal Stability Analysis 
Protein samples were prepared as for the far-UV and near-UV analysis as thermal assay is a 
thermodynamic application of the circular dichroism spectra for proteins.  However, the 
graphical output for the thermal profiles may be analysed from the original spectra in 
millidegrees (mdeg).  Figures 3.16 and 3.17 below illustrate the comparison of the thermal 
stability profiles of the wild type and mutant proteins.  The change of ellipticity was observed 
at 208 nm (I) 222 nm (II) over a temperature range between 20 and 90 °C.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.16 Comparative thermal analysis of wild type and mutants, measured at (I) 208 nm and (II) 
222 nm. Wild Type (green; n ), K98E (red; q ), K98R (blue; l ) and K98A (orange; Ï ).  Graphs were 
fitted to a two-state unfolding model and data expressed as a non-linear regression (Boltzmann 
sigmoidal plot).  Data is expressed in circular dichroism units, or millidegrees (mdeg). Graph images 
generated by GraphPad Prism, Version 6.01.  
II 
I 
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The melting Temperatures (Tm) for wild type and each mutant was determined from the fitted 
data, as described in Chapter 2, Figure 2.10. 
 
Table 3.10 The melting temperatures calculated from the non-linear regression curves of the two-state 
unfolding modelling. Data was calculated from the non-linear regression of the thermal profile at 222nm 
(Figure 3.16 II). 
 Wild Type K98E K98R K98A 
T(m) 68.7 ± 0.41 44.1 ± 0.14 33.4 ± 0.87 36.8 ± 0.08 
 
 
Data was fitted to a two-state unfolding model, as detailed in Chapter 2, and then converted to 
fraction of folded protein, as illustrated below in Figure 3.17. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.17 Fraction of folded protein as a function of temperature.  Graph legends are as follows: 
Wild Type (green; n ), K98E (red; q ), K98R (blue; l ) and K98A (orange; Ï ).  Graphs were fitted to a 
two-state unfolding model. Graph images generated by GraphPad Prism, Version 6.01. 
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Structural Analysis 
Following the structural analysis of the PBGD enzyme by UCSF Chimera, the interaction of 
the K98 residue with the DPM co-factor was visualized and a rationale established for the lack 
of co-factor binding in the case of the K98R and K98A mutants. Homology studies using the 
online bioinformatics server, Expasy was used, in order to observe the global effect on enzyme 
structure from each of the mutated sequences [109]. All Structures were minimised using 
Amber, and illustrations undertaken with USCF [61]. 
 
Figure 3.18 The superimposed structures of the modelled wild type enzyme from the CPH Model 
Server 3.0 (in tan colour) with the human crystal structure 3ECR (in grey). 
 
 
Figure 3.19 The active site of the PBGD enzyme.  
  
C261 
R149 
D99 
R150 
R173 
R195 
Q34 
K98 
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Figure 3.20 illustrates the wild type enzyme with the interactions of the lysine (K98) residue 
with the carboxyl oxygen of the DPM co-factor. The close vicinity of the K98 residue suggests 
a stable ionic interaction with the co-factor. The modelled structures did not contain the DPM 
co-factor; hence it was modelled in from the minimised crystal structure (3ECR). This, however, 
does not allow for the bond formation of the co-factor to the cysteine 261 residue. The K98E 
mutant, as shown in Figure 3.21, although not able to form ionic interactions with the carboxyl 
groups of the co-factor, appears to maintain some interaction with the amine groups within the 
C1 and C2 of the co-factor. 
Figure 3.20 The illustration of the wild type, K98 residue and the interaction with the DPM co-factor. 
 
Figure 3.21 The mutated K98E residue and the suggested interactions with the DPM co-factor amine 
groups.  
K98 
E98 
   64 
 
The K98R mutant, as shown in Figure 3.22, could possibly disrupt the architecture of the active 
site. The surface modelling shows how it interferes with the space occupancy of the DPM co-
factor. The K98A, on the other hand, as shown in Figure 3.23 had no possible interaction with 
the co-factor, as it has no polar charge and therefore cannot form any stable ionic interactions.  
From Figure 3.23 it seems plausible that the K98A may, in fact, disrupt protein folding, as the 
lack of a side chain renders the active site with an open gap, which may result in increased 
solvent exposure, and hence increased protein instability. 
Figure 3.22 The mutated K98R residue with surface modelling, illustrating the possible disruption to 
the active site as it interferes with the DPM co-factor.  
 
Figure 3.23 Mutated K98A residue with surface modelling, illustrating the lack of interaction of the 
alanine with the co-factor.  
R98 
A98 
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Homology modelling of the different mutants allowed for the speculation on observed changes 
in the overall structure of the enzyme.  As shown in Figure 3.24 with the K98E mutant (indicated 
in red) superimposed on the wild type (in tan), the active site loop appeared to assume a 
different conformation to that of the wild type (indicated by green arrows).  However, no other 
major differences were observed from the superimposed structures.  
 
 
Figure 3.24 The superimposed structures of the wild type (tan) and K98E (red) mutant from the 
homology modelled structures using CPH Models Server 3.0 [110]. Green arrows highlight differences 
from the wild type and mutant.  
 
 
 
Figure 3.25 The superimposed structures of the wild type (tan) and K98R (blue) mutant from the 
homology modelled structures using CPH Models Server 3.0 [110]. Green arrows highlight differences 
from the wild type and mutant  
   66 
 
In the K98R, as shown in Figure 3.25, the active site loop adopts a different conformation than 
the wild type enzyme, suggesting more of ‘open’ conformation, as discussed earlier in Chapter 
1, regarding the movement of the domains. In addition, there were some movements noted 
within the inner loop regions of the enzyme, which may support the observations of this 
mutant’s instability.  
 
The K98A mutant, as shown in Figure 3.26, similar to the K98R mutant, showed some changes 
of the active site loop conformation.  The active site loop appears to be further away from the 
other domains, again suggesting the ‘open’ conformation of the enzyme.  
 
 
Figure 3.26 The superimposed structures of the wild type (tan) and K98A (orange) mutant from the 
homology modelled structures using CPH Models Server 3.0 [110]. Green arrows highlight differences 
from the wild type and mutant  
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Discussion 
Overview 
The purpose of this dissertation was to provide an overview of AIP focussing on the PBGD 
structure and function as well as experimentally demonstrating the use of kinetic, structural 
and thermodynamic techniques to shed light on the enzyme, with the key focus to investigate 
the effects the three K98 mutations have on conformation and hence enzyme activity. Two 
clinically relevant PBGD mutants, K98E and K98R, were expressed. Both of these mutants 
have previously been described in patients; the K98R was first identified in a patient in 1995 
by Kauppinen et al., whereas the K98E mutation was identified by an MMed student in our 
laboratory in 2012 (reference to his MMed thesis https://open.uct.ac.za/handle/11427/6556) 
[1]. An additional mutant, K98A, was engineered and expressed in order to have a comparative 
view of the effect of charge at this residue.  None of these mutations have been characterised 
in the literature prior to this study. 
 
Site-Directed Mutagenesis 
The adaptation of the QuickChange® SDM proved successful for the generation of the K98E 
and K98R recombinant mutant plasmids (Figure 3.2). The standard protocol was adapted for 
the engineering of the K98A plasmid, which required a two-base pair change from AAG for 
lysine to GCG for alanine. The PCR reaction for the site-directed mutagenesis was adjusted 
to increase the number of cycles in order to accommodate for this change. 
 
Successful PCR products were obtained and expressed for the K98E and K98R mutants. 
There was initially some difficulty with the expression of the K98A mutant from overnight 
transfections. In order to address this, the antibiotic concentration was reduced as well as 
increased the volume of cells plated.  This was previously done for PPOX mutant proteins in 
our laboratory and proved a successful alternative protocol [92,111]. Screening of selected 
colonies by direct sequencing, as shown in Figure 3.2 proved that all three of the desired 
mutations in the K98 residue had been introduced.  As discussed in Chapter 2, further direct 
sequencing was also performed on the entire HMBS gene downstream of the K98 residue in 
order to ensure no other additional mutations had been introduced (data not shown). 
 
Expression and Purification of PBGD 
As this study included a kinetic and thermodynamic characterisation it was important that 
soluble, functionally assayable protein be expressed. Growth for 22 hours at 37⁰C without 
IPTG induction followed by non-denaturing TALON™ metal affinity chromatography was 
satisfactory to yield sufficient amounts of wild type and K98E protein for purification and 
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subsequent characterisation (see Table 3.3). For the K98A and K98R mutants the incubation 
time was increased to 24 hours as the expression of these two mutant proteins was low. This 
prolonged the growth period and we were able to obtain a satisfactory amount of protein.   
 
Imidazole based purification was used and this enabled the His-tagged PBGD to be 
competitively eluted off the column. The presence of high salt (NaCl) and TWEEN®-20 
detergent in the column load reduced the levels of non-specific protein binding. However, this 
protocol proved successful only for the wild type and the K98E proteins.  
 
Our visualization on the gradient SDS-PAGE electrophoresis showed that the eluted fractions 
for both the K98R and K98A contained several other protein fragments (Figure 3.4). This led 
us to speculate that 1) the expressed mutant protein was unstable and thus led to denaturation 
in cells or 2) due to the introduced mutation, there were several non-specific binding fractions 
that were interacting with the TALON™ resin. This non-specific binding is a common feature 
in recombinant expressed proteins [90,91].  
 
Owing to the non-specific binding and impure fractions within the K98R and K98A mutant 
proteins, we altered the protocol following a review of previous work in our lab with mutant 
enzymes [92]. The TALON™ resin volume was first reduced from 1.6 ml to 1.2 ml, whilst 
adding 5mM imidazole to the sonication buffer. Reducing the resin volume allows for 
decreased amount of sample to bind (and saturate) the resin beads.  In turn, it also then limits 
the amount of non-specific binding on the resin.  As shown in Figure 3.5 we were able to 
significantly reduce the large non-specific fragments that were eluting with our desired K98A 
PBGD protein.  However, there were still several small contaminating fragments in our 
samples.  Thus we further altered the protocol as follows:  The TALON™ resin was further 
reduced from 1.2 ml to 1.0 ml, and the imidazole concentration was further increased to 10mM 
in the sonication buffer.  As seen in Figures 3.6 and 3.7, this alteration reduced the non-specific 
binding whilst not affecting the yield of our desired PBGD protein.  The final adjustment in 
addition to those already mentioned, was to perform the entire purification at 4°C. This was 
done in order to promote the stability of the protein, and improved the purity of all our samples 
and was thus set as the new standard protocol for all purifications.  
 
There were several other issues with the purification of the K98A mutant that delayed further 
characterisation. The K98A mutant was highly unstable, and following elution of the purified 
protein fractions, the pooled fractions precipitated after only eight hours which was insufficient 
time to perform the required assays. In order to address this, we kept eluted fractions separate 
and did not pool all eluted protein following purification. The smaller the volume of sample, as 
well as the lower the concentration, the less likely a protein will precipitate. At the same time, 
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we pre-incubated the glass collecting tubes on ice, ensuring the protein remains as close to 
4°C as possible, at all times. This delayed precipitation to between 12 and 16 hours for the 
highest concentration protein fractions.  Upon further observation it was noted that the protein 
fractions with concentrations of 1 mg/ml and less, did not precipitate. Thus we diluted the high 
protein fractions to 1 mg/ml with the normal elution buffer (containing the correct amount of 
PMSF) directly after purification and protein quantification.  By doing so, we were able to 
prevent the precipitation of protein fractions for more than 72 hours, which was a sufficient time 
window to perform the required assays and analyses. 
 
When analysing the quality of each purification with SDS PAGE electrophoresis, we utilised 
the Coomasssie®–R250 stain.  Although Vacutec Aqua Stain product is advertised as being 
able to detect nanomolar quantities of protein, it provided satisfactorily results for the wild type 
and was a faster and more convenient approach, the non-specific binding fractions could not 
be observed with this method in the mutants. False assumptions regarding purity were thus a 
potential problem using the latter stain. 
 
Specific Activity  
Wild type PBGD protein and each of the generated mutants were tested for specific activity 
with the use of the modified assay by Anderson and Desnick [118]. The assay is based on the 
production of HMB from the PBG substrate, which is non-enzymatically converted to 
uroporphyrinogen, and oxidised to fluorescent uroporphyrin I (as detailed in Chapter 2, Figure 
2.5). We initially had some issues pertaining to the solubility of the uroporhyrin I standard, 
which was not soluble in the Tris/HCl assay buffer, but following some additional research we 
were able to determine that it would be soluble in a stronger molarity of hydrochloric acid (HCl) 
[119]. The initial stock solution of 1mg/ml uroporphyrin I was made up in a 5N HCl solution in 
order to have the uroporphyrin I soluble, whereas the aliquoted standard solutions were in a 
0.5N solution of HCl (as further detailed in Appendix 17). 
 
Optimization of the assay had to be performed for each of the mutant PBGD proteins, and the 
protein concentration measured and taken into account during the conversion of fluorescent 
units to specific activity (Chapter 2).  For the low expressing mutations, K98A and K98R, 
significantly higher protein concentrations were required in order to have accurate and 
meaningful fluorescent readings.  
 
K98R is known to be an AIP-causing mutation associated with the phenotype of this autosomal 
dominant disease. This fits with our measurements which showed it had negligible activity and 
would result in approximately 50% activity in AIP subjects as such patients could be assumed 
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to have inherited the dysfunctional K98R allele plus a normal allele from the unaffected parent 
[26,57]. The K98E mutant showed 54% of the wild type PBGD specific activity. K98E has also 
been shown to be an AIP-causing mutation (reference to MMed thesis 
https://open.uct.ac.za/handle/11427/6556) although PBGD activity was not measured in 
patient blood samples. We could predict that the PBGD activity measured in such a patient’s 
blood should reveal approximately 75% of normal activity. We were not able to follow up with 
such an investigation as fresh blood samples from this patient were unobtainable (reference 
to MMed thesis https://open.uct.ac.za/handle/11427/6556). With regards to the K98R and 
K98A mutant proteins, the specific activity was negligible for both, with results below 1% in 
relation to wild type (Table 3.4). It therefore appears that these mutations either disrupt the 
active site architecture or alternatively affect the protein folding, both of which render the 
enzyme inactive.  
 
Kinetic Characterisation 
For determining the kinetic constants of each of the respective samples, the specific activity 
assay was modified in order to ensure achieving substrate excess and the determination of 
the kinetic constants from the Michaelis-Menten fitted curves, as illustrated in Figure 3.8.  All 
assays were performed a minimum of three times from independently purified samples in order 
to ensure reproducibility.    
 
The Michaelis constant (KM) determined for wild-type PBGD in this study agrees with that of 
Meissner (1990) (KM of 8.7 µM), and the more recent work of Roberts et al. (2013) [68,120].  It 
also falls within the region of previously published PBGD KM (4-20 µM), as reviewed for HMBS 
(EC 2.5.1.61) from the online enzyme database BRENDA (http://www.brenda-enzymes.info) 
[120,121].   With regards to the engineered mutants, the K98R had a similar KM to the wild-
type, suggesting that the affinity of the enzyme for its PBG substrate is unaffected by the 
mutation (Table 3.5; Figure 3.9). In contrast, the K98E mutant had an approximately three-fold 
increase of KM in comparison to wild type showing a significant loss of substrate affinity (Table 
3.5; Figure 3.9). A KM for K98A could not be determined. We initially speculated that the K98A 
mutant would mimic the K98E by having a significantly larger KM (in comparison to the wild 
type), indicative of a loss of substrate affinity. However, during the activity and kinetic assays, 
the total enzyme activity was almost negligible, and even after several attempts and alterations 
to the protocol, the KM had an unrealistic variation in values, either very low numbers, (close 
to zero) or values as high as 100  µM. In other repeated attempts, data was scattered and did 
not converge, hence no kinetic constants could be determined.  One possible reason for this 
might be due to the effect of small variations on almost negligible activity. In other words, 
because the fluorescent readings are within the lowest reading frame (at highest sensitivity 
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settings on the fluorimeter), a small amount of variation results in drastic scattering of activity 
reflected in the final calculation [122,123]. Although it may well be that the K98A mutant has a 
weak affinity towards the PBG substrate, the instability of the protein together with its negligible 
activity makes it impossible to accurately determine the KM. 
 
In terms of the enzyme’s catalytic efficiency, in other words the rate of substrate converted to 
product, taking into account both enzyme and substrate concentrations, expressed as the ratio 
of kcat/KM, it may be noted that the K98E as well as the K98R have a four-fold and eight-fold 
(respectively) lower enzyme efficiency compared to the wild type (Table 5.5). This implies that 
although the specific activity of the K98E is only half that of the wild-type PBGD enzyme, the 
loss of the substrate affinity (KM) consequently results in the enzyme turnover rate to be 
practically negligible. Similarly, in the case of the K98R, even though the substrate is still able 
to bind, the negligible activity results in an equally poor enzyme catalytic function. These 
findings support the fact that the K98E and K98R are known disease causing mutations 
(https://open.uct.ac.za/handle/11427/6556) [117]. Since we were not able to determine a 
stable KM for the K98A, we were consequently unable to determine the catalytic efficiency for 
this mutation. However, based on the close resemblance of this mutant’s activity to that of the 
K98R, together with its significant instability, it may be suggested that that this mutant has 
almost no enzymatic function.   
 
Native PAGE Analysis 
The native PAGE is often used as a technique to view and profile the different enzyme 
complexes of the PBGD enzyme [124].  As highlighted previously in chapter 2, the stability of 
the enzyme during the polymerization steps, allows for the viewing of each respective enzyme-
substrate complex. We anticipated that the analysis of the accumulation of different enzyme 
complexes may allow for some insight into how a specific mutation may affect the enzyme 
function in either the inability of the enzyme to polymerize its substrate (accumulation of the 
first two complexes) or difficulties pertaining to the release of the product (accumulation of the 
final enzyme-substrate complex ES4) (Figure 1.11). 
 
The initial investigation of the native PAGE gels showed mostly smearing of bands, or 
alternatively no product was seen. We attempted several different protocols without success. 
Finally, following contact and discussions with Ms Helene J. Bustad, from the University of 
Bergen in Norway, who published an article with relation to similar work (in Norwegian 
mutations) as we have done for the K98, including native PAGE gels, we achieved some 
results by using her protocol [96]. We also adapted the system in order to perform these native 
PAGE gels in the smaller and Bio-Rad® electrophoresis systems which allowed for reduced 
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running time of the gel.  Finally, following the successful visualization of the wild type ES 
complexes (Figure 3.10), we adapted to run our mutant samples at 4°C, as the stability was a 
continuous issue.  However, as illustrated in Figure 3.10, all of our mutants proved too unstable 
for this native PAGE analysis and showed mostly band ‘smearing’.  The K98E showed a faint 
band, higher up on the gel in comparison to the ES complex of the wild type, which has been 
previously suggested to be a partially formed holoenzyme [96,124].  In other words, the K98E 
mutant maintains interaction of the co-factor (holoenzyme), but there are some issues 
pertaining to the protein folding. This is particularly interesting as this might explain why the 
K98E mutant is able to retain 54% of its activity in comparison to the wild type, but at the same 
time show a significant difference in secondary structure and a lack of thermal/conformational 
stability. 
 
It would have have been interesting to expand on these native PAGE gels with the addition of 
the PBG substrate, in order to see how each mutation would respond, and thereby promote 
the understanding of how each mutation affects the enzyme mechanism. However, 
considering that no enzyme complex bands could be observed for any of our mutants, it was 
not possible to do so.  In addition, it has been previously reported that the PBGD enzyme is 
destabilised upon substrate binding, thereby further promoting destabilisation to already highly 
unstable mutants would not yield positive results [75,96].  We did, however, attempt a native 
PAGE with the addition of PBG to each respective mutant prior to the running of the native 
PAGE gel, but no changes were observed.   
 
DPM Co-Factor Analysis 
During the first attempts to purify the K98R mutant, it was noted that the eluted mutant protein 
lacked the characteristic pink colour (due to presence of a pyrrolic chromophore of the DPM). 
This led us to speculate (in subsequent repeated purifications with the same outcome) that 
there could possibly be a loss of the DPM co-factor in this mutant [71]. Following subsequent 
testing of the wild type PBGD as well as our mutants using the original assay performed by 
Hart et al. (1988) in their work on the DPM co-factor, we were able to show that the K98R had 
lost its ability to bind the DPM co-factor, since there was no spectral shift in the absorbance, 
which is a key feature of PBGD with bound vs. unbound DPM (Figure 3.11) [78]. On the other 
hand K98E was able to retain co-factor binding ability (Figure 3.11) as demonstrated by 
retention of the spectral shift.  Based on these results, we speculated that the K98A mutant 
would have the combined effects noted in each of these mutants, namely a loss of substrate 
affinity (KM) as well as a loss of co-factor interaction. Indeed the K98A mutant showed no 
interaction with the enzyme’s native DPM co-factor but we could not ascertain substrate 
binding affinity as outlined in the previous section.   
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As detailed in Chapter 1, the DPM co-factor is a striking and significant feature of functional 
PBGD enzyme.  Among other residues within the vicinity of the enzyme active site, the K98 
has been suggested to be important for the interaction and maintenance of the co-factor 
orientation.  However, no evidence has been put forward to prove this.  Thus with our K98 
mutants, we agree with this speculation, and have provided results to support that the K98 is 
indeed a key residue for co-factor interaction as mutation(s) of the residue results in failure of 
the enzyme to bind its co-factor. In contrast, the PBGD mutation in the glutamate residue (E) 
maintains the co-factor binding. A possible reason for this is that the negative glutamate, 
although no longer able to form ionic interactions with the carboxyl groups of the co-factor, 
may be able to form ionic interactions with the amine rings of the co-factor, thereby stabilising 
the enzyme and maintaining a stable co-factor interaction. In the case of K98R it could be 
speculated that the bulky arginine (R) side chain disrupts the orientation and architecture within 
the active site cleft, and consequently disrupts the niche of specific interactions of the co-factor.  
Alternatively, perhaps the arginine interferes with the orientation of the D99 residue, as 
previously discussed to be a key residue for enzyme catalysis, thereby destabilizing the ionic 
interactions of the enzyme with the DPM co-factor on more than one residue simultaneously.  
On the other hand, the K98A which lacks a side chain as well as polar charge, results in an 
opening or gap within the active site, thus increasing the solvent exposure of the active site.  
This could be one possible reason why this mutant is particularly unstable.  
 
DPM Co-Factor Removal 
One of our aims was to investigate first the removal of the DPM co-factor, followed by re-
addition of the DPM co-factor and or PBG (substrate). The method of Hart et al. (1988) has 
been cited several times in the literature as a means of the most reproducible and successful 
method for the removal of the DPM- co-factor from native wild type enzyme [78].  An alternative 
methodology for ‘removal’ of the co-factor was to not generate the PBG required for co-factor 
formation and insertion in the first place. Such involves the generation of a vector that mutates 
the hemA gene, and consequently ALA synthase, which produces the PBG substrate, is not 
produced. However, this methodology was beyond the scope of this work, and assumed the 
first-mentioned method was viable [58,80,125].   
 
Initially there was a significant number of problems with the methodology from Hart et al. 
(1988), and we attempted several optimization strategies, including the use of alternate buffers 
to the sodium phosphate buffers used by them. Tris/HCl buffers were chosen in order to 
accommodate the required pH of 8.0 versus 7.2 as used by Hart et al. (1988) [78].  Further, 
following increased dialysis buffer exchanges, allowed for successful removal of the co-factor 
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from the enzyme, as indicated from the results, with the lack of a spectral shift noted in the 
treated ‘apo’ enzyme sample (Figure 3.11).   
 
The presumed ‘apo’ enzyme sample was very unstable, and had a specific activity below 2%.  
Our results were in agreement with the published results from Hart et al. (1988) as we were 
able to recover a similar amount of protein following dialysis; they stated a recovery of 36% of 
the original protein concentration and in our results we were able to achieve 34% from the 
original protein [78]. This, of course, made it increasingly difficult to obtain sufficient quantities 
of protein for our analysis, so we overcame this by hydrolysing multiple samples 
simultaneously.  Because of the instability of the protein, we kept all fractions separate (similar 
to that of K98R and K98A) rather than pooling the samples, in order to prevent protein 
precipitation.  The timing and planning around the acid hydrolysis and dialysis of the so called 
‘apo’ enzyme was crucial, as the protein precipitated completely overnight.  
 
PBGD Reconstitution Assay 
As highlighted earlier, our aim was to test whether we would be able to ‘rescue’ the ‘apo’ 
enzyme from which co-factor had been removed, by adding back DPM co-factor.  The rationale 
was as follows:  As suggested in Chapter 1, it has been shown that there are two ways in which 
the PBGD enzyme is able to obtain its DPM co-factor, the one involving reaction with the use 
of the product, HMB (or preuroporhyrinogen) or the alternative slower reaction with the use of 
the monopyrrolic PBG substrate.  Thus we evaluated what effect it would have if, instead of 
the preuorporphhyrinogen product, the DPM co-factor per se was pre-incubated with the 
enzyme. The further downstream experiments, if this first experiment had proved successful 
(i.e. in which the wild type enzyme had the co-factor successfully removed and reconstituted), 
would have been to perform similar assays with the K98R and K98A, in order to evaluate if 
indeed the enzyme would be able to take up and bind the DPM co-factor and thus promote the 
stability of the enzyme as a whole. In addition, it would have been interesting to evaluate and 
produce the kinetic parameters involved in the binding of the co-factor to the enzyme.  
 
As detailed in Chapter 3, we were only able to achieve 22.4% activity of the ‘apo’ enzyme in 
comparison to wild type after addition of/pre-incubation with the DPM co-factor, PBG substrate 
or both (Table 3.7).  There were no differences between the addition of the substrate only 
versus the pre-incubation of the enzyme with the DPM co-factor (Table 3.7).  Thus there is no 
evidence to suggest that the enzyme shows any preference for the DPM co-factor over the 
PBG substrate under these experimental conditions. Hence the use/binding of the dipyrrolic 
form of the co-factor appears no more efficient/preferred than the monopyrrolic PBG. In 
addition, there is no additive/synergistic effect seen by the co-factor and the substrate.   
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We performed several optimization strategies and alterations to the protocol in order to test 
whether our reconstituted activities could possibly be improved. For example, the solubility of 
the DPM co-factor was also tested and adapted from the prescribed solvent of pure methanol, 
which we felt could have been problematic to the refolding/reconstitution of the protein.  We 
were able to dissolve the DPM in a 50% v/v of methanol and imidazole solution.  This solution 
did not have any effect on the native wild type enzyme (Table 3.7). We also used a 
concentrated DPM solution (0.5 mM), in order to maintain the volume of the methanol-
imidazole solution added in each assay sample, to a minimum (Appendix 21).  Further, the 
assay time was increased to 4 hours to ensure the co-factor reconstitution reaction could run 
to completion, keeping in mind the slow ‘lag’ phase suggested for the ‘apo’ enzyme when 
utilising either PBG and/or possibly the DPM co-factor. The additional assay time was also 
allowed to ensure that our fluorescence readings were within an accurate range.  We also ran 
an additional assay at 4°C, in parallel to the normal assay at 37°C, in order to test whether the 
higher temperature results in spontaneous oxidation of the co-factor which would be 
problematic.  As detailed in Chapter 1, the DPM co-factor is quite prone to oxidation, which 
renders the enzyme inactive [70].  Indeed, we noted that in some of our samples the solution 
turned bright yellow following completion of the assay.  However, the assays performed at 4°C 
showed negligible activity restoration after reconstitution with DPM (and/or PBG), even 
following the prolonged incubation time of the assay.  We performed additional assays for a 6-
hour period, but no improvement of the results was observed.  
 
It could be argued that either the enzyme is not completely functional at 4°C, as most assays 
for PBGD are performed at physiological temperature (37°C) [40,126]. Alternatively, it could 
be that the higher temperature does promote some oxidation of the DPM co-factor, thereby 
making it non-viable for the enzyme to utilise. As noted in Chapter 1, the oxidised co-factor is 
observed to have a different conformation in comparison to the reduced form. This change in 
conformation may lead to a reduced reactivity of the DPM co-factor, which might be a possible 
reason for the enzyme not to favour the DPM co-factor versus the PBG substrate.  As quoted 
from Awan et al. (1997) in their work with the preference of the PBGD enzyme to 
preuroporphyrinogen:   
 
“The answer undoubtedly lies in the fact that the 1-hydroxymethyl group of 
preuroporphyrinogen is more reactive than the aminomethyl group of porphobilinogen and 
more readily forms a azafulvene that can rapidly alkylate cysteine-361 to form the thioether 
link...” [73]. 
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An alternative scenario that could possibly explain the low recovered activity is that the PBGD 
enzyme has previously been shown to be destabilised upon PBG substrate binding. This 
correlates with the suggestion that the enzyme is able to ‘open’ and ‘close’ in order to 
accommodate the growing pyrrole product (as discussed in Chapter 1) [75,96]. Thus, 
considering the unstable nature of the ‘apo’ enzyme, the binding of the PBG causing additional 
destabilisation may lead to an enzyme that is not entirely functional.  In contrast to all of these 
scenarios it is also possible to speculate that the enzyme was not correctly refolded during the 
dialysis and was consequently dysfunctional to start off with. Further work to establish this was 
beyond the scope of this study within funded and required time period –  although an answer 
could be sought by a host of different experiments to investigate protein folding and 
aggregation, including intrinsic and extrinsic fluorescence, CD and NMR [127]. 
 
CD Far – UV Analysis 
As noted in Chapter 1, the K98 residue has been suggested to be important for enzyme 
catalysis.  Based on our findings of the K98R and K98A whereby the interaction with the DPM 
co-factor is lost, we wanted to investigate whether this loss possibly correlates with alterations 
in the enzyme secondary structure (i.e. the general three dimensional form of local segments 
of the PBGD protein).  Our rationale was that although the K98 has been suggested to be 
important in enzyme catalysis, we may be able to further define its role by establishing whether 
or not it was important for conformational stability of the protein.   
 
The methodology for our CD far-UV analysis was based on the recent work of Bustad et al. 
(2013) in other PBGD mutants [96].  The only modification to their methods was the use of 
ammonium sulphate buffer instead of potassium fluoride (KF). Ammonium sulphate has the 
same lower wavelength limit as potassium fluoride (185 nm) and was within our range of 
spectra measurements [98].  In addition all of our eluted protein samples required buffer 
exchanges, as the high content of imidazole in the elution buffer is optically active and would 
therefore adversely affect the spectral data [98]. All of our samples were surprisingly stable in 
the exchanged CD buffer (data not shown). The buffer exchange results in approximately a 
one and half times dilution, thus we had to perform a protein quantification after the samples 
were exchanged into the CD buffer.  This is particularly important when performing repeat 
experiments, and also since we are comparing the ellipticity amongst all of our mutants.  
Changes in concentration might result in changes of data recorded and thus lead to false 
results and/or artefacts and incorrect conclusions.  
 
Once CD spectral data was collected we analysed the data for our different mutants. We 
utilised CDPro software which has three different algorithms namely, the CDSstr, CONTINLL 
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and SELCON 3 [100–104]. CDPro is a robust program since it allows for the analysis of three 
different algorithms which can be referenced against a dataset of ten proteins.  Importantly, 
although the data was normalized for the graphical display of the far-UV analysis, we used 
only the raw data which had been minimised against the blank. The CDPro algorithms only 
read spectra within the range of 180 nm to 240 nm and therefore data was only collected 
between 190 nm and 240 nm.  We did not include spectra below 190 nm as the buffer 
absorbance increases exponentially from this point and it is generally advised to keep the 
absorbance below 2.0 absorbance units.  
 
As shown in Table 3.8, our results indicate that there are modest differences in secondary 
structure estimates between the WT and mutant PBGD. It is important to note that these 
structure estimations are done based on a reference set of proteins for each algorithm.  The 
data may be considered as valid estimations if there is convergence amongst the estimations 
of each algorithm.  From the data we can observe that there is a decreased α-helical content 
predicted for the K98E and K98R in comparison to wild type.  However, the difference is only 
significant for the α-helical prediction of K98E, as noted in Chapter 3 (Table 3.8).  This is 
particularly interesting as it suggests that the ‘non-conservative’ change from the positive 
lysine to the negative glutamate, does hinder the secondary α-helical structure. In terms of the 
β-sheet estimation, although the K98R and K98A appeared to have increased estimations (as 
noted in Table 3.8) the changes were not significant. This finding is interesting as the loss of 
the co-factor we found for both these mutants, there was an expectation that some secondary 
changes would be observed. 
 
In addition to the analysis with the CDPro software, we also performed two other analyses of 
predictions for the PBGD enzyme secondary structure.  These included the predictions based 
from the crystal structures PBGD enzyme, as well as another software package CDNN 
[106,112,114].  The comparison of the wild type to the known human crystal structures was 
done in order to determine if our results are within the same range as for the crystal structure.  
As shown in Table 3.9, we compared the mean secondary structure prediction of the wild type 
to the two human PBGD crystal structures (3ECR and 3EQ1) [60,67]. The two algorithms, 
DSSP and STRIDE are able to integrate the coordination points of the crystal structure and 
provide a prediction of the enzyme secondary structure.  Although our results are within the 
same range as the predictions of DSSP and STRIDE, it appears that the ratio of α-helices and 
β-sheets differ slightly. However, our results are in agreement with Bustad et al. (2013), who 
also found a higher β-sheet and lower α-helix prediction [96]. It could be argued that crystal 
structures, although providing some insight into the possible structure, will naturally vary from 
a native functional enzyme.   
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To further investigate the secondary structure predications, we analysed the data using CDNN.  
Although this program does not have multiple algorithms, it screens the data against protein 
reference sets and provides a global picture of all of the possible structure predictions.  Indeed 
as noted in Figure 3.14, the CDNN software allows for the differentiation of β-sheets and 
parallel sheets. Interestingly, here we are able to observe that the K98E shows a variation of 
its secondary structure, with a decrease in predicted α-helical content, and an increase in β-
sheets. The K98A, in contrast seems to have a similar α-helical content compared to the wild 
type, whereas its β-sheet content is decreased. This might provide an explanation for the 
instability of the K98A PBGD [128]. 
 
CD Near – UV analysis 
Whereas changes in the far-UV CD will usually reflect major backbone changes in the protein, 
small conformational changes are more likely to be detected in a near-UV analysis since the 
CD contributions of the aromatic side chains is usually very sensitive to their environment 
[129,130]. Thus, the near-UV analysis (260 nm – 300 nm) was carried out in order to 
investigate whether the mutation of K98 affected the spectra of the aromatic amino acids in 
PBGD (phenylalanine, tyrosine and tryptophan) [115,131]. Although this does not provide an 
in-depth structural insight of the enzyme as a whole, the ‘tertiary footprint’ of these amino acids 
does allow for a comparison of the wild type to each of the respective mutants [97].   
 
For the near-UV analysis, the data was treated the same as for the far-UV. The final graphic 
output was then adjusted in order to only include the spectra for the wavelength range from 
260 nm to 300 nm.  From Figure 3.15 illustrating the peaks observed for phenylalanine, 
tyrosine and tryptophan there is an indication that the aromatic rings, specifically tyrosine, is 
disrupted in each of the mutants.  As noted in Chapter 3, all of the mutants illustrate a ‘blue-
shift’ towards the lower wavelength of the tyrosine movement and possible increased exposure 
to solvent.  This suggests that the alteration of the K98 residue does indeed disrupt some of 
the active site architecture and may alter the conformation of the enzyme.  The K98E however 
seems to retain the intensity of the ellipticity signal, whereas the K98R and especially the K98A 
illustrates an intensity shift towards zero, indicating the ‘quenching’ of the signal.  This may 
further support the idea of the loss of co-factor in these two mutants as the quenching is as a 
result of exposure to either surrounding water, or alternative polar environments [130,132].   
 
Thermal Stability Analysis 
The PBGD enzyme is known to be thermally stable and therefore does not readily unfold with 
increases in temperature [68,86].  However considering the effect of the K98R and K98A 
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mutation on the enzyme’s stability, we wanted to further characterise the effect of these 
mutations by investigating their effects on the enzyme’s thermal stability.  
 
The PBGD mutations caused alterations in the spectral profiles over a temperature range of 
20 – 90 °C (Figure 3.16).  The wild type illustrates a high conformational stability, with a melting 
temperature (T(m)) of 68.7°C, which correlates with previous studies on PBGD [68,72]. The 
K98E, which is the most stable of all the mutants in terms of protein activity, however shows a 
similar sensitivity to thermal denaturation as the K98R and K98A (Table 3.10). The signal at 
222 nm for all of the mutants is significantly reduced in comparison to wild type, which again 
highlights the instability of the mutants. The K98R, unlike the K98E and K98A, seems to have 
a more linear (or flatter) regression. This is also seen in Figure 3.17, where the graphs were 
fitted in order to express data as a fraction of folded protein.  The K98A unfolds very rapidly, 
followed by the K98E.  The K98R, again illustrates a slower transition from folded to unfolded 
protein. Attempts to fit multiple sets of data from different, independent purifications illustrated 
the same trend. This may highlight the arginine residue (R) itself, indicating that although the 
K98A also has negligible activity, the arginine may be disrupting additional residue networks 
and interactions.  
 
Structural Analysis 
A structural analysis was undertaken to allow for further visualization of the possible effect of 
each mutation in terms of the enzyme structure.  We chose the human crystal structure (PDB 
ID: 3ECR) published from Song et al. (2009) [67].  The rationale being that the alternative 
human model from Gill et al (2009) was crystallised with the R167Q mutation [60].   Bung et 
al. (2014) used the E.coli protein in their work using molecular dynamics – as it is the best 
characterised [75].  However, we chose to maintain the analysis in the human, un-mutated 
enzyme. An online server, hosted by the global database and bioinformatics tool, Expasy was 
used for the homology modelling of the PBGD mutants [109].  CPHModels 3.0 Server allowed 
for the simple uploading of the sequences (in FASTA) format, followed by the prediction model 
based on all known crystal structures of the sequence.    
 
Figure 3.18 illustrates the superimposed structure of our wild type modelled query to the known 
human crystal 3ECR.  As detailed in Chapter 3, there is a clear and direct overlay of the 
enzyme, and the missing active site loop region was successfully modelled.  This gave us a 
good indication that the homology modelling proved successful and we could continue with 
further analysis. Importantly, each of the structures were independently minimised following 
the modelling, as well as an energy minimisation of 3ECR performed prior to superimposing 
of structures. 
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With regards to the global structural analysis of the enzyme, from Figures 3.24 – 3.26 in 
Chapter 3, it is evident that there are some changes of the active site loop conformation.  What 
is very interesting, and somewhat surprising, is that each of the respective K98 mutations 
seems to affect the active site loop conformation in a different way.  In Figure 3.24 it can be 
seen that the K98E mutation appears to change the conformation of the active site loop. It 
assumes a more ‘closed’ conformation as it moves towards the other domains in comparison 
to wild type.  This may be an effect of the negative glutamate charge.  The active site cleft as 
highlighted in Chapter 1, has predominant positively charged residues. So it could be argued 
that the negative glutamate, although it does allow for some means of stabilisation from the 
interaction with the DPM co-factor, as is suggested in Figure 3.21, may cause destabilisation 
of surrounding residues within the positive active site. In addition this might also explain the 
significant reduction in substrate affinity, as the active site loop adapts a more closed 
conformation which may reduce the availability of the enzyme to its PBG substrate.  
Furthermore, the altered conformation of the loop may also correlate to the significantly 
reduced α-helical content noted in the far-UV analysis for the K98E (Chapter 3, Table 3.8).  
 
With regards to the K98R (Figure 3.25) and the K98A (Figure 3.26) mutants, the opposite effect 
is seen. The active site loop resembles more of an ‘open’ conformation, which is normally 
adapted for the enzyme with the release of the product, as shown by Bung et al. (2013) (and 
previously discussed in Chapter 1) [75]. The surface modelling of the bulky arginine, as shown 
in Figure 3.22, indicates that there is a possible steric hindrance with the DPM co-factor that 
might result in a change in conformation or positioning of the co-factor. In doing so it may 
however promote the oxidation of the co-factor, as suggested by Azim et al. (2014) (and 
discussed in Chapter 1, Figure 1.10). [70]. A similar picture may be seen from the K98A 
mutation.  The active site loop is seen to move away from the other domains (in comparison 
to the wild type), again suggesting the ‘open’ conformation of the enzyme. In contrast to the 
K98R, the alanine has no charge, as seen in Figure 3.23, which in turn may further destabilize 
the enzyme, as the lack of a side chain may create an additional open area within the active 
site. This opening may render the enzyme open to increased solvent exposure, which may 
disrupt the conformation of the enzyme as a whole. 
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Conclusions 
The purpose of this study was to investigate how a range of mutations within the active site (at 
the K98 residue) of PBGD affects the enzyme mechanism and conformation. In general terms, 
our results support the idea that expansion of our knowledge of a single active site residue 
may provide important insight into the structure and function of the PBGD enzyme as a whole.  
 
Site directed mutagenesis and expression of the K98E, K98R and K98A PBGD variants were 
successfully carried out. Furthermore, purification using affinity chromatography was optimised 
in order to obtain satisfactory pure and soluble protein for kinetic and spectroscopic 
characterisation. Compared to wild-type PBGD, K98R and K98A had negligible specific activity 
and the K98E had approximately 50% of wild-type specific activity. In K98R and K98E mutants 
the catalytic efficiency was significantly reduced. K98R had a similar KM to that of wild-type, 
but K98E showed reduced substrate binding affinity. These kinetic parameters could not be 
determined in K98A due to protein stability issues. The significance of the positive charge of 
the K98 residue on substrate affinity was illustrated by a significant loss of substrate affinity 
(higher KM) in the negatively charged K98E mutant, whereas the conservative mutation, K98R, 
had a similar KM to that of the wild type enzyme. However, the fact that the K98E mutant was 
partially functional suggested that the positive charge in the lysine residue is not a critical 
requirement for substrate conversion. 
 
We also studied DPM co-factor binding using a spectral shift assay. We conclude that the lack 
of activity seen in the K98R and K98A mutants were as a result of failure to bind the DPM co-
factor. The K98E, in contrast, retains binding of the DPM co-factor which could be explained 
through structural modelling, illustrating potential interaction between the negatively-charged 
carbonyl oxygens on the glutamate (E) residue and the positive amine groups in the DPM co-
factor. 
 
In addition, we were able to establish a protocol for native PAGE analysis in order to observe 
the enzyme-substrate complexes for the wild type enzyme. However, we could not achieve 
such with any of the mutant PBGDs, as they were too unstable, even with attempted 
optimization strategies. We therefore could not determine the effect of each of the respective 
mutations on the enzyme-substrate complexes required for conversion of PBG substrate to 
HMB product, using this methodology. 
 
Further investigation of the DPM co-factor binding interaction proved successful in part, as we 
were able to remove the co-factor. However, attempts to reconstitute the wild type enzyme 
from the ‘apo’ enzyme by re-addition of the DPM co-factor were unsuccessful.  We found no 
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evidence that the ‘apo’ enzyme shows a preference for the DPM co-factor versus the PBG 
substrate; however, it is likely that further methodological optimization is needed. The 
generated ‘apo’ enzyme is unstable, and the methodology from Hart et al. (1988) for the 
refolding of the protein is not ideal, as the protein recovery is too low to perform further analysis 
[78]. Due to time constraints, we were unable to adapt a different protocol for the protein 
refolding. 
 
We successfully established a protocol for the analysis of the secondary structure for each of 
our mutants using far-UV analysis, as well as spectral observations of the ‘tertiary footprint’ 
from near-UV analysis.  The K98E mutant PBGD illustrated significant changes in its α-helical 
content, thereby suggesting that the negative glutamate may interfere with other residues 
within the positive active site cleft. The K98R and K98A showed marginal differences, however 
none of these changes were significant. The near–UV analysis, on the other hand, allowed for 
speculation regarding the stability of each of the mutants, from the observations of spectral 
shifts of aromatic rings. The blue shift of the tyrosine seen in all of the mutants may indicate 
increased exposure to solvent, and hence a decrease in protein stability. The ‘quenching’ of 
the ellipticity signal observed in the K98R and K98A may correlate with changes in enzyme 
conformation.   
 
In addition, the thermal stability assays we performed further illustrated the instability of the 
mutants.  The wild type demonstrated the characteristic high thermal stability, whereas, each 
of the mutants had melting temperatures slightly above normal biological temperature (37°C).   
 
The structural analysis and modelling of each of the mutants allowed for the correlation of the 
kinetic and thermodynamic results, as well as the co-factor assay. Based on molecular 
modelling, K98E may retain co-factor interaction by forming ionic interactions with the amine 
groups of the co-factor (as mentioned). In contrast, the bulky arginine of K98R may sterically 
hinder the binding of the DPM co-factor. The K98A has no ability to form an ionic network, 
which allowed us to speculate that it promotes increased solvent exposure, thus supporting 
the instability of this mutant.  Homology modelling of each of the mutants to the wild type 
illustrated that there might be possible changes in conformation of the active site loop.  This 
finding may explain the compromised kinetic function of the mutants as well as the 
conformational results. 
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Future Recommendations 
It would be interesting to test the kinetics of the DPM co-factor binding with the use of 
isothermal calorimetry.  In brief, this technique analyses changes in heat from binding and 
dissociation, which would enable the calculation of the dissociation constant kd. Future work 
should aim to generate the ‘apo’ enzyme via the silencing of the hemA gene.  Previous work 
has shown a great success of this method, which enables the growth and culturing of the ‘apo’ 
PBGD. In brief, the silencing of the hemA gene results in a lack of transcription of the ALAS 
enzyme, and therefore no PBG can be produced.  
 
A crystal structure of the human K98E would also be advantageous. This might provide an 
insight into the effect of the negative charge within the active site and how the enzyme is able 
to retain co-factor binding.  In addition, it would be good to be able to visualize the effect of the 
mutation on the active site loop, provided the human enzyme allows for the crystallisation of 
this area (which could not be determined in previously published crystals of the human 
enzyme, due to distortion of this area). 
 
Finally, there should be a follow-up on the work of Bung et al. (2014) in terms of molecular 
dynamics [75].  Not only for the K98, but for highlighted residues within the active site as well.  
This may provide further insight into movement of the domains, the movement of the active 
site loop, and the interaction network within the active site as a whole. 
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Appendix 1 – Human nucleotide HMBS Sequence (non-erythroid form) 
 
cDNA Sequence (GenBank ID: NM_000190.3) 
CCGGAAGTGACGCGAGGCTCTGCGGAGACCAGGAGTCAGACTGTAGGACGACCTCGGGTCCCACGTGTCCCCGGT
ACTCGCCGGCCGGAGCCCCCGGCTTCCCGGGGCCGGGGGACCTTAGCGGCACCCACACACAGCCTACTTTCCAAG
CGGAGCCATGTCTGGTAACGGCAATGCGGCTGCAACGGCGGAAGAAAACAGCCCAAAGATGAGAGTGATTCGCGT
GGGTACCCGCAAGAGCCAGCTTGCTCGCATACAGACGGACAGTGTGGTGGCAACATTGAAAGCCTCGTACCCTGG
CCTGCAGTTTGAAATCATTGCTATGTCCACCACAGGGGACAAGATTCTTGATACTGCACTCTCTAAGATTGGAGA
GAAAAGCCTGTTTACCAAGGAGCTTGAACATGCCCTGGAGAAGAATGAAGTGGACCTGGTTGTTCACTCCTTGAA
GGACCTGCCCACTGTGCTTCCTCCTGGCTTCACCATCGGAGCCATCTGCAAGCGGGAAAACCCTCATGATGCTGT
TGTCTTTCACCCAAAATTTGTTGGGAAACCCTAGAAACCCTGCCAGAGAAGAGTGTGGTGGGAACCAGCTCCCTG
CGAAGAGCAGCCCAGCTGCAGGAAAGTTCCCGCATCTGGAGTTCAGGAGTATTCGGGGAAACCTCAACACCCGGC
TTCGGAAGCTGGACGAGCAGCAGGAGTTCAGTGCCATCATCCTGGCAACAGCTGGCCTGCAGCGCATGGGCTGGC
ACAACCGGGTGGGGCAGATCCTGCACCCTGAGGAATGCATGTATGCTGTGGGCCAGGGGGCCTTGGGCGTGGAAG
TGCGAGCCAAGGACCAGGACATCTTGGATCTGGTGGGTGTGCTGCACGATCCCGAGACTCTGCTTCGCTGCATCG
CTGAAAGGGCCTTCCTGAGGCACCTGGAAGGAGGCTGCAGTGTGCCAGTAGCCGTGCATACAGCTATGAAGGATG
GGCAACTGTACCTGACTGGAGGAGTCTGGAGTCTAGACGGCTCAGATAGCATACAAGAGACCATGCAGGCTACCA
TCCATGTCCCTGCCCAGCATGAAGATGGCCCTGAGGATGACCCACAGTTGGTAGGCATCACTGCTCGTAACATTC
CACGAGGGCCCCAGTTGGCTGCCCAGAACTTGGGCATCAGCCTGGCCAACTTGTTGCTGAGCAAAGGAGCCAAAA
ACATCCTGGATGTTGCACGGCAGCTTAACGATGCCCATTAACTGGTTTGTGGGGCACAGATGCCTGGGTTGCTGC
TGTCCAGTGCCTACATCCCGGGCCTCAGTGCCCCATTCTCACTGCTATCTGGGGAGTGATTACCCCGGGAGACTG
AACTGCAGGGTTCAAGCCTTCCAGGGATTTGCCTCACCTTGGGGCCTTGATGACTGCCTTGCCTCCTCAGTATGT
GGGGGCTTCATCTCTTTAGAGAAGTCCAAGCAACAGCCTTTGAATGTAACCAATCCTACTAATAAACCAGTTCTG
AAGGTGTAAAAAAAAAAAAAAAAA 
 
Amino Acid Sequence (GenBank ID: P08397.2) 
 
MSGNGNAAATAEENSPKMRVIRVGTRKSQLARIQTDSVVATLKASYPGLQFEIIAMSTTGDKILDTALSKIGEKS
LFTKELEHALEKNEVDLVVHSLKDLPTVLPPGFTIGAICKRENPHDAVVFHPKFVGKTLETLPEKSVVGTSSLRR
AAQLQRKFPHLEFRSIRGNLNTRLRKLDEQQEFSAIILATAGLQRMGWHNRVGQILHPEECMYAVGQGALGVEVR
AKDQDILDLVGVLHDPETLLRCIAERAFLRHLEGGCSVPVAVHTAMKDGQLYLTGGVWSLDGSDSIQETMQATIH
VPAQHEDGPEDDPQLVGITARNIPRGPQLAAQNLGISLANLLLSKGAKNILDVARQLNDAH 
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Appendix 2 – Primers for Human HMBS Sequence 
 
Fragment 1 
GGCACTCGACCGGAATTATCGATTAACTTTATTATTAAAAATTAAAGAGGTATATATTAATGTATCGATTAAATA
AGGAGGAATAAACCATGGGGGGTTCTCATCATCATCATCATCATGGTATGGATGTCTGGTAACGGCAATGCGGCT
GCAACGGCGGAAGAAAACAGCCCAAAGATGAGAGTGATTCGCGTGGGTACCCGCAAGAGCCAGCTTGCTCGCATA
CAGACGGACAGTGTGGTGGCAACATTGAAAGCCTCGTACCCTGGCCTGCAGTTTGAAATCATTGCTATGTCCACC
ACAGGGGACAAGATTCTTGATACTGCACTCTCTAAGATTGGAGAGAAAAGCCTGTTTACCAAGGAGCTTGAACAT
GCCCTGGAGAAGAATGAAGTGGACCTGGTTGTTCACTCCTTGAAGGACCTGCCCACTGTGCTTCCTCCTGGCTTC
ACCATCGGAGCCATCTGCAAGCGGGAAAACCCTCATGATGCTGTTGTCTTTCACCCAAAATTTGTTGGGAAGACC
CTAGAAACCCTGCCAGAGAAGAGTGTGGTGGGAACCAGCTCCCTGCGAAGAGCAGCCCAGCTGCAGAGAAAGTTC
CCGCATCTGGAGTTCAGGAGTATTCGGGGAAACCTCAACACCCGGCTTCGGAAGCTGGACGAGCAGCAGGAGTTC
AG 
 
Fragment 2 
CGCATCTGGAGTTCAGGAGTATTCGGGGAAACCTCAACACCCGGCTTCGGAAGCTGGACGAGCAGCAGGAGTTCA
GTGCCATCATCCTGGCAACAGCTGGCCTGCAGCGCATGGGCTGGCACAACCGGGTGGGGCAGATCCTGCACCCTG
AGGAATGCATGTATGCTGTGGGCCAGGGGGCCTTGGGCGTGGAAGTGCGAGCCAAGGACCAGGACATCTTGGATC
TGGTGGGTGTGCTGCACGATCCCGAGACTCTGCTTCGCTGCATCGCTGAAAGGGCCTTCCTGAGGCACCTGGAAG
GAGGCTGCAGTGTGCCAGTAGCCGTGCATACAGCTATGAAGGATGGGCAACTGTACCTGACTGGAGGAGTCTGGA
GTCTAGACGGCTCAGATAGCATACAAGAGACCATGCAGGCTACCATCCATGTCCCTGCCCAGCATGAAGATGGCC
CTGAGGATGACCCACAGTTGGTAGGCATCACTGCTCGTAACATTCCACGAGGGCCCCAGTTGGCTGCCCAGAACT
TGGGCATCAGCCTGGCCAACTTGTTGCTGAGCAAAGGAGCCAAAAACATCCTGGATGTTGCACGGCAGCTTAACG
ATGCCCATTAACTAGCATGACTGGTGGACAGCAAATGGGTCGGGATCTGTACGACGATGACGATAAGGATCGATG
GGGATCCGAGCTCGAGATCTGCAGCTGGTACCATATGGGAATTCGAAGCTTGGCTGTTTTGGCGGATGAGAGAAG
ATTTTCAGCCTGATACAGATTAAATCAGAACGCAGAAGCGGTCT 
  
VecHMBS1F [+1] 
HMBS1R 
K98 
HMBS2F 
Stop 
VecHMBS2R 
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Appendix 3 – Media 
 
Equipment 
Autoclave Huxley, Speedy (Laboratory and Scientific Co. (Pty) Ltd., Cape Town, South Africa) 
 
Reagents 
§ Agar Noble (Biolab Diagnostics, Gauteng, South Africa) 
§ Ampicillin 100mg/ml 
§ Bacto® - Yeast Extract  
§ Bacto® - Tryptone 
§ NaCl 
 
Methodology 
 
Luria-Bertani (LB) Medium 1L pH 7.5 
 
§ Weigh out the following reagents: 
 
NaCl 5.0 g 
Yeast Extract 5.0 g 
Tryptone 10.0 g 
 
§ Add 1L distilled water to dissolve 
§ Sterilise by autoclaving 
Store at 4⁰C 
 
 
LB Agar Plates 200mL pH 7.5 
 
§ Weigh out the following reagents: 
Agar 3.0 g 
NaCl 1.0 g 
Tryptone 2.0 g 
Yeast Extract 1.0 g 
 
§ Add 200 ml distilled water to dissolve 
§ Sterilise by autoclaving 
 
§ Allow to cool to approximately 35 – 45 ⁰C (warm to touch) 
§ Add 0.25 ml ampicillin (100 mg/ml stock) 
§ Pipette 20 ml into Petri dishes (pipette to the side to prevent bubble formation) 
§ Allow 20 minutes to cool/set with lid slightly open to prevent condensation 
§ Close lid and seal dish with parafilm 
 
Store inverted at 4⁰C in sealed plastic bag 
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Appendix 4 – Generation and Storage HMBS stocks 
 
Equipment 
• Orbital shaker incubator (Yidher LM-510, Taiwan) 
• Sterile Falcon™ Round-Bottom Polypropylene Tubes (15 ml) (Fischer Scientific, 
Pittsburgh) 
• Cryo-storage tubes (2 ml) (Bio-Rad Laboratories, Munich, Germany) 
 
Reagents 
• 100 mg/ml Ampicillin 
• LB medium 
• Sterile 100% Glycerol 
 
Methodology 
§ Inoculate 6 ml LB medium containing ampicillin (0.1 mg/ml) with 6 µl E.coli JM109 
HMBS plasmid (from overnight culture) 
§ Incubate at 37⁰C on shaking incubator (225 rpm) overnight (14 - 18 hours) 
 
§ Pipette 300 µl of glycerol and 700 µl of culture into 2 ml cryo-storage tubes 
§ Mix by inverting (± 6 times) 
§ Label appropriately 
 
Store at -80⁰C 
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Appendix 5 – Plasmid DNA Isolation (from E.coli) 
Protocol from Wizard® Plus SV Minipreps DNA Purification kit (Promega Corporation, 
Madison, USA) 
 
Equipment 
§ Hermle Z400 centrifuge (Laboratory and Scientific Equipment Co. (Pty) Ltd., Cape 
Town, RSA) 
§ Labnet Spectrafuge 24D (Labnet International, Inc., Edison, NJ, USA) 
§ 1.5 ml Sterile microcentrifuge tubes (Axygen Scientific Inc., Union City, CA, USA) 
 
Methodology 
§ Centrifuge 6 ml overnight culture (Appendix 4) at 4000xg for 10 minutes 
§ Discard supernatant (LB Waste); resuspend pellet with 250 µl Cell Resuspension 
solution 
§ Transfer resuspended sample to a 1.5 ml microcentrifuge tube 
 
§ Add 250 µl Cell Lysis solution to sample; mix by inverting 4 - 6 times 
§ Incubate at room temperature until solution clears (4 - 5 minutes) 
§ Add 10 µl Alkaline Protease Solution; mix by inverting 4 - 6 times 
§ Incubate at room temperature for exactly 5 minutes 
 
§ Add 350 µl Neutralization Solution; mix by inverting 4 - 6 times 
§ Centrifuge at 14000xg for 10 minutes at room temperature 
§ Place column into collection tube. Label both column and collection tube clearly 
§ Pipette approximately 850 µl (maximum) of supernatant into column; centrifuge at 
14000xg for 1 - 2 minutes 
§ Discard flow through and re-insert column into collection tube 
 
§ Importantly: leave small amount of supernatant behind above precipitate to ensure no 
precipitate is pipetted out with supernatant.  If, however, traces of precipitate are 
observed -pipette into sterile microcentrifuge tube and centrifuge at 14000xg for 5 
minutes. Transfer supernatant into column 
 
§ Add 750 µl of Wash Solution to column; centrifuge at 14000xg for 1 - 2 minutes 
§ Discard flow through and re-insert column into collection tube 
 
§ Repeat wash procedure with 250 µl of Wash solution; Centrifuge at 14000xg for 2 
minutes 
§ Transfer column into a sterile 1.5 ml microcentrifuge tube; add 50 µl of Nuclease-free 
water directly on to membrane in column. 
§ Incubate at room temperature for 2 minutes 
§ Elute DNA by centrifuging at 14000xg for 2 minutes 
§ Quantify DNA and determine purity (Appendix 6) 
 
Store at -20⁰C 
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Appendix 6 – DNA Quantification 
Equipment 
§ Gene Quant Spectrophotometer (Pharmacia Biotech, Cambridge, UK) 
§ Glass capillaries (Separation Scientific, Honeydew, RSA) 
 
Reagents 
§ Reference/ Blank (nuclease-free water used to elute purified DNA – Appendix 5) 
§ Extracted DNA (Appendix 5) 
 
Methodology 
§ Set GeneQuant for double stranded DNA 
§ Path Length 0.5 mm 
§ Factor dsDNA 
§ Tare GeneQuant: 
 
§ Aliquot 5 µl of reference into sterile 0.5 microcentrifuge tube 
§ Dip capillary into reference sample until approximately 3/4 of the capillary is filled with 
solution 
§ Prevent solution from leaking out by sealing top end of capillary with a small amount of 
Presstick 
§ Remove excess solution on the outside of capillary by wiping with clean paper towel 
§ “Blank” GeneQuant using reference sample 
 
Quantifying DNA 
§ Insert capillary into sample as described above 
§ Read the O.D of the DNA and note the percentage purity, DNA concentration and the 
260:280 ratio  
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Appendix 7 – Primer (Oligonucleotide) Design & Preparation for use 
 
Equipment 
§ Vortex - 2 Genie (Scientific Industries Inc., Bohemia, NY, USA) 
§ Primer Designer 
 
Internet Sources 
§ Oligo analyser (Integrated DNA Technologies Inc. Coralville, Iowa 52241, USA) 
 
Table A7.1 Table of Primers designed for screening of SDM mutants. 
Primer Name Region 5’--- 3’ base pairs 
VecHMBS1F Vector 5’-GGC ACT CGA CCG GAA TTA TC-3’ 20 
HMBS1R HMBS 5’-CTG AAC TCC TGC TGC TCG TC-3’ 20 
HMBS2F HMBS 5’-CGC ATC TGG AGT TCA GGA G-3’ 19 
VecHMBS2R Vector 5’-AGA CCG CTT CTG CGT TCT G-3’ 19 
     F -  Forward; R - Reverse; Vec - Vector; 1&2 - Fragment numbers 
 
Preparation for use: 
§ Briefly spin tube containing primer (oligo) 
§ Resuspend oligo in 1 ml sterile water 
§ Incubate at room temperature for a minimum of 20 minutes 
§ Vortex to ensure oligo is completely dissolved, and spin down briefly 
§ Prepare working stocks of 25 µM (20 µl aliquots) 
 
Store at -20° C 
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Appendix 8 – Agarose Gel Electrophoresis 
 
Equipment: 
§ BioRad® Sub cell GT System for agarose gels (Bio-Rad Laboratories, Munich, 
Germany) 
§ BioRad® GT UVTP gel tray 15x7 cm (Bio-Rad Laboratories, Munich, Germany) 
§ PS-1500 DC power supply (Hoefer Scientific Instruments, San Francisco, USA) 
§ UVItech gel documentation system (UVItech, Limited, Cambridge, UK) 
 
Reagents: 
§ Seakem LE agarose (Whitehead Scientific, Cape Town, RSA) 
§ 10 x TAE Buffer (pH 8.0) 
§ 1 mg/ml ethidium bromide (Sigma-Aldrich, St. Louis, MO, USA) 
§ Sucrose sample solution 
o 30g sucrose 
o 10 mg Bromophenol blue 
o 5 ml 0.5M Na2EDTA (pH 8.0) 
 
Methodology: 
§ Weigh out agarose (for 1% gel = 0.5 g in 50 ml 1 x TAE) in 250 ml flask and add TAE 
§ Microwave agarose and cool briefly 
§ Add 10 µl of 1 mg/ml ethidium bromide, mix and pour into gel tray 
§ Insert spacer and allow to set 
§ Pour 1 x TAE buffer to cover gel in gel tank 
§ Load samples (2:1 ratio with sucrose sample solution) 
§ Run gel at 100 V for 1.5 hours 
§ Visualize gel using UVItech documentation system 
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Appendix 9 – QuickChange® Site-Directed Mutagenesis 
 
Equipment and Reagents 
§ 0.6 ml sterile PCR microcentrifuge tubes (Axygen Scientific Inc., Union City, USA) 
§ GeneQuant spectrophotometer (Pharmacia Biotech, Cambridge, UK) 
§ Hybaid Omnigene thermal cycler (The Scientific Group, Cape Town, RSA) 
§ Labnet Spectrafuge 24D (Labnet International, Inc., Edison, NJ, USA) 
§ Orbital Shaker Incubator (Yidher LM-510, Taiwan) 
§ SI-18 incubator (Stuart Scientific, Laboratory and Scientific Equipment Co. (Pty) Ltd., 
Cape Town, RSA) 
§ Sterile 17 x 100 mm polypropylene tubes (Laboratory and Scientific Equipment Co. 
(Pty) Ltd., Cape Town, RSA) 
§ Water Bath (Memmert, Laboratory and Scientific Equipment Co. (Pty) Ltd., Cape Town, 
RSA) 
 
Reagents 
§ Agar Plates (Appendix 3) 
§ DpnI restriction endonuclease (Fermentas, Life Sciences, Inqaba Biotech, RSA) 
§ Mutagenic oligonucleotides (Integrated DNA Technologies Inc., Coralville, IA, USA) 
§ Pfu Turbo® Buffer (Promega Corporation, Madison, W1, USA) 
§ Pfu Turbo® DNA polymerase (Promega Corporation, Madison, W1, USA) 
§ SABAX sterile, d.H2O (Adcock Ingram Critical Care, Johannesburg, RSA) 
 
Methodology: 
 
9.1 Mutagenic Oligonucleotide design  
 
1.  Design two complementary mutagenic oligonucleotides containing the desired base 
change.   The desired mutation should be centered in the primer with 10 - 15 bases of wild 
type sequence on either side.  It is highly recommended that the designed oligo ends with a G 
or C nucleotide in order to stabilize the oligo during the annealing between oligo and the 
template. 
 
2.  Using Oligonucleotide parameter analyser determines the GC content, melting temperature 
(Tm); self-dimer and heterodimer as well as ΔG.  
Parameter Minimum Maximum Optimum 
%GC 40 60 55 
length 25 45 25 
*The Tm of the hairpin as well as oligo hetero-dimer should be lowers than the annealing 
temperature of the reaction. 
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3.  Select a restriction enzyme from a relevant website (for example Webcutter 2.0) to 
enable restriction analysis to be performed that will allow for identification between the mutant 
and the wild type. 
Table A9.1 HMBS mutant primers (oligos) 
Mutant Sequence Length (bp) 
K98E.F 5’-GTTCACTCCTTGGAGGACCTGCCCAC-3’ 
26 
K98E.R 5’-GTGGGCAGGTCCTCCAAGGAGTGAAC-3’ 
K98R.F 5’-GTTCACTCCTTGAGGGACCTGCCCAC-3’ 
26 
K98R.R 5’-GTGGGCAGGTCCCTCAAGGAGTGAAC-3’ 
K98A.F 5’-GTTGTTCACTCCTTGGCGGACCTGCCC-3’ 
27 
K98A.R 5’- CAGTGGGCAGGTCCGCCAAGGAGTGA-3’ 
 
9.2 DNA Extraction 
See Appendix 5 
 
9.3 Mutant Strand Synthesis - Polymerase Chain Reaction 
 
Reagents 
§ 10 x Reaction Buffer 
§ 10 µM mutagenic oligos (Table A9.1) 
§ d.H2O 
§ dNTPs (25 mM) 
§ dsDNA (10 ng/µl) 
§ Pfu Turbo® polymerase (100U) 
 
Methodology 
Table A9.2 PCR Reaction Set up 
Reagent Final Concentration Volume (µl) 
Reaction Buffer (10 X) 1 X 5 
dNTPs (25 mM) 10 mM 2 
Forward and Reverse Mutagenic Primers (10 µM) 7.4 µM  2 (each) 
Pfu Turbo® polymerase (3 U/µl) 1 U 0.5 
d.H2O  25.5 
Purified DNA (50 ng/µl) 10 ng/µl 5 
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For each sample add 37 µl of master mix. Hereafter determine amount of magnesium to be 
added; 
50 µl reaction 
Tube Samples DNA (µl) H2O (µl) Mg2+ (µl) 
No DNA - 13 0 
 No Mg2+ 
5 
8 0 
2 mM Mg2+ 4 4 
4 mM Mg2+ 0 8 
 
Take care not to vortex to prevent bubble formation; flick samples to mix and spin down briefly 
 
Table A9.3 Hybaid Omnigene Program Cycle - For one base change 
 Temperature (⁰C) Time (minutes) Number of Cycles 
Initiation Denaturation 94 5:00 1 
Denaturation 94 0:30 
12# (16**) Annealing 55 0:30 
Elongation 72 12:00* 
* Protocol stipulates 2 min/kb; HMBS together with insert = ± 6kb 
# Number of cycles equals 12 for single base pair change. Wild type – AAG; K98E – GAG; 
K98R – AGG 
** For a 2 base pair change mutation 16 cycles are required. K98A – GCG 
 
§ Place samples on ice following PCR 
§ Confirmation of PCR product 
o Run samples on a 0.8% agarose gel (Appendix 8) 
o Add 8 µl ethidium bromide (1mg/ml) to gel prior to pouring 
o Mix & load 5 µl of PCR product + 5 µl d.H2O + 1.5 µl loading dye 
o Run gel at 80 V 
 
§ Select strongest and purest  PCR product 
§  DpnI RE digest of PCR product 
o 45 µl PCR product 
o 2 µl DpnI 
o 4.7 µl DpnI buffer added directly to sample 
o Centrifuge samples briefly 
o Incubate at 37⁰C for one hour 
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9.4 Transformation 
§ Chill 17 x 100 mm falcon tubes on ice 
§ Allow stored JM109 cells (stored at - 70⁰C) to thaw on ice 
 
§ Immediately aliquot 100 µl JM109 cells into chilled falcon tubes 
§ Add 5 - 10 µl of digested product (ensure no mineral oil is included); flick 4 - 6 times 
§ Incubate on ice or 30 minutes 
§ Heat shock reaction exactly - 42⁰C water bath for 45 seconds 
§ Immediately place on ice for 2 minutes 
 
§ Add 900 µl LB media, incubate with shaking incubator (225 rpm) at 37⁰C for 1 hour 
§ Transfer to a 1.5 ml microfuge tube 
§ Spin down cells at 4000xg for 2 minutes 
§ Discard 900 µl of supernatant and resuspend cells with remaining supernatant 
§ Spread previously prepared agar plate (Appendix 3) with 50 µl of transformed JM109 
cells 
§ Leave to air dry for ± 20 minutes 
§ Invert plates and incubate at 37⁰C overnight  
§ Visible single clones may be isolated and inoculated for expression (Appendix 4) 
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Appendix 10 – Amplification of HMBS using Polymerase Chain Reaction (PCR) 
 
Equipment and Reagents 
§ 0.6 ml sterile PCR microcentrifuge tubes (Axygen Scientific Inc., Union City, USA) 
§ GeneQuant spectrophotometer (Pharmacia Biotech, Cambridge, UK) 
§ Labnet MultiGene OptiMax Thermal Cycler. (The Scientific Group, Cape Town, RSA) 
§ Labnet Spectrafuge 24D (Labnet International, Inc., Edison, NJ, USA) 
§ Vortex - 2 Genie (Scientific Industries Inc., Bohemia, NY, USA) 
§ Microcentrifuge tubes 1.5 ml and 0.5 ml (Axygen Scientific Inc., Union City, USA) 
 
Reagents: 
§ GoTaq Flexi (Promega Corporation, Madison, W1, USA) 
§ Magnesium-free DNA polymerase 5 x Buffer (Promega Corporation, Madison, W1, 
USA) 
§ 25 mM MgCl2 (Promega Corporation, Madison, W1, USA) 
§ Deoxynucleotide triphosphate (dNTPs) (Promega Corporation, Madison, W1, USA) 
o dATP, dCTP, dGTP, dTTP 
§ Designed primers (see Appendix 9) 
§ SABAX sterile, d.H2O (Adcock Ingram Critical Care, Johannesburg, RSA) 
 
Methodology: 
§ Set up PCR reaction (master mix) in a 1.5 ml microcentrifuge tube on ice for the number 
of desired reactions. 
 
Table A10.1 The standard PCR reaction mixture 
Reagent Final Concentration Volume (µl) 
Buffer (5 X) 1 X 10 
Deoxynucleotide triphosphates; dNTPs (2.5 mM) 100 µM 1 
Forward and Reverse Primers (25 µM) 0.5 µM  1(each) 
GoTaq flexi DNA Polymerase (5 U/ µl) 1 U 0.2 
MgCl2 (25 mM) 1.5 mM 3 
Purified DNA (100-200 ng/µl) 
For Negative Control used d.HO 
2 – 4 ng/ µl 1 
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§ Aliquot 49 µl of master mix into a 0.5 ml microcentrifuge tube 
§ Add 1 µl DNA (100-200 ng) 
§ Add 1µl of H2O to the blank 
§ Mix and spin down briefly 
 
Note: The PCR cycling conditions used for the HMBS primers were all optimised, and it was 
found that the annealing temperature (Ta) for all primer pairs was 58⁰C.  
 
Table A10.2 The PCR Cycling Conditions for the HMBS Primers.  
 Temperature (⁰C) Time (minutes) Number of Cycles 
Initiation 95 1:00 1 
DNA Denaturation 95 0:30 
35 Annealing 58 0:30 
Elongation 72 0:30 
Final Extension 72 8:00 1 
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Appendix 11 - 6% Non-Denaturing Polyacrylamide Gel Electrophoresis (PAGE) 
 
Equipment: 
§ 50 ml glass measuring cylinder 
§ 100 ml glass beaker 
§ Hoefer vertical slab gel electrophoresis unit, SE600 series (Hoefer Scientific 
Instruments, San Francisco, USA) 
o Glass gel plates 
o Spacer comb (1.5 mm) 
o Clamps 
o Combs and spacers (1.5 mm) 
o Casting stand 
o Upper & lower buffer chambers 
 
§ Hamilton blunt end syringe (The Hamilton Company, Nevada, USA) 
§ PS1500 DC power supply (Hoefer Scientific Instruments, San Francisco, USA) 
§ UVItec gel documentation system (UVItec Limited, Cambridge, UK) 
 
Reagents 
§ 10 X TBE Buffer  pH 8.0 
§ Tris/HCL  890 mM 
§ Boric acid  890 mM 
§ EDTA   20 mM 
 
§ 30% acrylamide, 0.8% bis-acrylamide (A-Bis-A) 
§ 10% ammonium persulphate (Promega Corporation, Madison, W1, USA) 
§ TEMED (N,N,N',N', - Tetramethyl-ethelenediamine) 
Store at 4 ⁰C 
 
§ Sucrose sample solution (Loading Dye) 
o Sucrose   30 g 
o Bromophenol Blue  10 mg 
o Na2EDTA  (0.5M ; pH 8) 5 mL 
 
§ Make up to a total volume of 50 mL with d.H2O 
§ Store in aliquots at - 20 ⁰C 
 
§ Ethidium Bromide 
o 100 µl of 1 mg/ml stock solution in 200 ml d.H2O (Sigma-Aldrich, St. Louis, MO, 
USA) 
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Methodology 
§ Assemble glass plates (using 1.5 mm spacers) with clamps; mount plates on casting 
stand 
§ 6% Gel Solution (50 mL Glass Cylinder) 
o 10 x TBE Buffer      4 ml 
o A-Bis-A       8 ml 
o Add d.H2O to a final volume of 40 ml; then add, 
o TEMED       40 µl 
o Ammonium persulphate     400 µl 
 
§ Mix Gel Solution by pouring into 50 ml Glass Beaker 
§ Pour solution into the space between the clamped plates in the gel casting stand 
§ Insert 20 bay sample comb 
§ Allow gel to polymerize at room temperature for minimum of 30 minutes 
§ Assemble upper chamber buffer on top of gel plates with clamps and fill with 500 ml  
1 x TBE 
§ Fill lower chamber with 1L 1 x TBE 
§ Prepare 10 µl of samples and molecular marker (1:1 with loading dye solution) 
§ Load samples into gel wells using Hamilton syringe 
§ Run gel at 250 V for 1.5 hours 
§ Remove gel from between glass plates and allow to stain in a solution of ethidium 
bromide for 10 minutes 
§ Rinse in d.H2O 
§ Visualize gel on UVltec documentation system and photograph 
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Appendix 12 – DNA Purification from PCR Product 
 
Equipment and Reagents: 
§ 1.5 ml microfuge tubes (Greiner, Lasec, Cape Town, South Africa) 
§ SABAX sterile d.H2O (Adcock Ingram Critical Care, Johannesburg, South Africa) 
§ IllustraTM GFXTM PCR DNA and Gel Band Purification Kit (Amersham Biosciences Ltd.) 
§ Labnet Spectrafuge 24D Centrifuge (Labnet International Inc.) 
§ Vortex – 2 Genie G560-E Mixer (Scientific Industries Inc 
 
Methodology: 
§ Transfer PCR product into a sterile 1.5 ml microfuge tube 
§ Add 500 µl Capture buffer type 3 (blue cap) 
§ Mix solution thoroughly 
§ Spin down briefly 
 
§ Place GFX column into a sterile collection tube 
§ Transfer the capture buffer 3 and sample mixture into the GFX column 
§ Centrifuge at 14000xg for 40 seconds 
§ Discard flow through in the collection tube. Reinsert GFX column back into collection 
tube 
 
§ Add 500 µl of wash buffer type 1 (yellow cap) 
§ Centrifuge at 14000xg for 40 seconds; discard flow through in the collection tube 
§ Repeat with 250 µl of wash buffer type 1 
 
§ Place GFX column into a sterile 1.5 ml microfuge tube 
§ Add 30 µl elution buffer type 6 (pink cap) directly onto membrane in the GFX column 
§ Incubate at room temperature for 2 minutes 
§ Centrifuge at 14000xg for 1 minute 
 
§ Determine DNA concentration and purity using the GeneQuant spectrophotometer 
 (Appendix 6); use the elution buffer type 6 as the reference 
 
Store at - 20⁰C 
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Appendix 13 – TALONTM Affinity Protein Purification 
 
Equipment and Reagents 
§ Orbital Shaker Incubator (Yidher LM-510, Taiwan) 
§ Refrigerated Centrifuge (Centrikon T-324, Kontron Instruments, Italy) 
§ Misonix Sonicator 300 (Laboratory and Scientific Equipment Co. (Pty) Ltd., Cape Town, 
RSA) 
§ Source 15Q glass column (6 mm x 300 mm) (Amicon Ltd, Stonehouse, UK) 
§ Gilson Minipuls 3 Pump (Laboratory and Scientific Equipment Co. (Pty) Ltd., Cape 
Town, RSA) 
§ Glass pipettes 
§ Small sterile glass test tubes (12 x 75 mm) (B&M Scientific, Cape Town, South Africa) 
 
Reagents: 
§ TALON® metal affinity Resin (Clonetch Laboratories, Palo Alto, CA, USA) 
§ Phenyl-methyl-sulfonyl fluoride (PMSF) (10mg/ml) Sigma-Aldrich, St. Louis, MO, USA) 
o PMSF 100 mg 
o Isopropanol 10 ml 
 
§ Sonication Buffer pH 8.0 
o Tris-HCl 20 mM 
o NaCl 100 mM 
o Tween-20 1% 
 
§ Equilibration Buffer pH 8.0 
o Tris-HCl 20 mM 
o NaCl 100 mM 
o Tween-20 0.5% 
 
§ Wash Buffer pH 8.0 
o Tris-HCl 20 mM 
o NaCl 100 mM 
o Tween-20 0.5% 
o Imidazole 25 mM 
 
§ Elution Buffer pH 8.0 
o Tris-HCl 20 mM 
o NaCl 100 mM 
o Tween-20 0.5% 
o Imidazole 150 mM  
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Methodology: 
§ Inoculate 1 ml of stock cells and 1 ml ampicillin (100 mg/ml) into 1L LB Media (Appendix 
3) 
§ Incubate on shaker (225 rpm) at 37⁰C for 22 hours 
§ Aliquot culture into centrifuge tubes of 125 ml 
§ Centrifuge for 30 minutes at 4⁰C and 3000 g  
§ Discard supernatant; resuspend pellets in 30 ml sonication buffer + 30 µl PMSF; use 
the club shaped glass rod 
§ Avoid ‘frothing’ and bubble formation during re-suspension 
 
Sonication: 
§ In a plastic beaker, sonicate solution using the macro-probe of the Sonicator 
§ Sonicate sample at 60 Watts for 30 seconds; keep probe at the bottom of beaker to 
prevent ‘frothing’ 
§ Place sample on ice for 2 minutes – prevent overheating and consequent protein 
denaturation 
§ Repeat 30 second sonication another three times; keep on ice following every 
sonication 
§ Ultracentrifuge sonicate at 4⁰C (105000 g) for 30 minutes 
§ Collect supernatant for column and label (LOAD); note volume 
 
Column Preparation: 
§ Set up the column on a retort stand, so that column is approximately 10 cm from bottom   
§ Connect the column to the pump by connecting plastic tubing 
§ Add 1.0 ml of resin into the column and allow to settle 
§ Equilibrate the column with 10 ml of equilibration buffer (containing 10 µl of PMSF); 
take care not to disrupt resin bed 
§ PBGD is light sensitive; cover resin with aluminium foil 
 
Protein binding and elution 
§ Load the supernatant of sonicate into the column (rate 15 ml/hr) 
§ Collect flow-through in fractions; pool samples and label VOID; note volume 
§ Add 10 ml equilibration buffer (with 10 µl PMSF) to ensure binding of final load to 
column; after 20 minutes increase rate to 16-18 ml/hr 
§ Add 10 ml wash buffer (with 10 µl PMSF) and collect in fractions; label WASH; note 
volume 
 
§ To elute protein: Add 10 ml elution buffer (with 10 µl PMSF) to column 
§ Clamp and remove tubing from pump; 
§ Collect flow through in fractions of 10 drops per tube (approximately 500 µl) 
§ Collect 6-8 fraction samples 
§ Pool all samples (PBGD) and note final volume 
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Appendix 14 – 7.5 – 15.5% Gradient SDS Polyacrylamide Gel Electrophoresis (PAGE) 
 
Equipment and Reagents 
§ Hoefer vertical slab gel electrophoresis unit (SE600 Series) (Amersham Pharmacia 
Biotechnology Inc.) 
§ UVITech Gel Documentation apparatus, (UVItech, Limited, Cambridge, UK) 
§ K65HM High-density synthetic paper (Whitehead Scientific) 
§ SG Gradient Maker (Hoefer Scientific Instruments, San Francisco, CA, USA) 
§ 25 ml glass measuring cylinders 
§ 10 ml volumetric Flask 
Additional Reagents 
§ 17.5% Resolving solution (in 25 ml measuring cylinder) 
o 7 ml “High” Buffer (1M Tris/HCl, pH 8.8, 30% glycerol) 
o 12 ml A-Bis-A Solution (30% Acrylamide, 0.8% bis-acrylamide) 
o 0.3 ml 10% SDS 
o Make up to 20 ml with d.H2O and mix well 
 
§ 7.5% Resolving solution (in 25 ml measuring cylinder) 
o 7 ml “Low” Buffer (1M Tris/HCl, pH 8.8, 7.5% glycerol) 
o 5 ml A-Bis-A Solution (30% Acrylamide, 0.8% bisacrylamide) 
o 0.3 ml 10% SDS 
o Make up to 20 ml with d.H2O and mix well 
 
§ Spacer Solution (in 10 ml volumetric Flask) 
o 1.2 ml A-Bis-A Solution 
o 8.6 ml spacer buffer (0.125 M Tris/HCl, pH 6.8) 
o 0.1 ml 10% SDS 
Methodology 
§ Boil samples for 5 minutes with an equal volume of 2% SDS, 0.2% mercaptoethanol, 
20% glycerol and 0.002% bromophenol blue in 0.125 M Tris/HCl pH 6.8 
§ To each resolving solution add 100µl of freshly prepared 5% ammonium persulphate 
and 10 µl TEMED immediately before use. Mix Well. 
§ Set up glass plates with 1.5 mm spacers and mount on casting stand 
§ Pour 16 ml of both solutions into the gradient pourer.  The low solution in the left 
chamber and the high solution in the right chamber – containing a stirrer and placed on 
a magnetic plate 
§ Introduce water at the top 
§ Once resolving gel has set add spacer solution containing freshly prepared 100µl 15% 
ammonium persulphate and 10µl TEMED 
§ Insert 1.5 mm comb 
§ Load samples into wells using Hamilton syringe 
§ Run gel at 80 V for 16 hours 
§ Track bromophenol blue to asses gel front; should be 1.5 cm from the bottom 
§ Remove the gel between plates 
§ Stain gel (Appendix 15) 
§ Visualize gel using UVItech documentation system  
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Appendix 15 – Coomassie® R-250 PAGE Gel Staining 
 
Equipment  
§ UVITech Gel Documentation apparatus, (UVItech, Limited, Cambridge, UK) 
§ K65HM High-density synthetic paper (Whitehead Scientific) 
§ Plastic container (old microtip box) 
  
Reagents 
§ Staining Solution 
o 0.1% Coomassie® R250 Brilliant Blue Dye (Life Technologies, South Africa) 
o 50% MeOH 
o 10% glacial acetic acid 
 
§ De-staining solution  
o 40% MeOH 
o 10% glacial acetic acid 
 
§ Storage Solution  
o 5% glacial acetic acid 
 
Methodology: 
§ Stain for 20-30 minutes on shaker 
§ Decant stain (Can be re-used 2-3 times). 
§ De-stain gel on shaker 
o Use small amount and exchange every 15-20 minutes* 
*Place sponge in box to aid the de-staining 
§ Store in final solution 
§ Visualize gel using UVItech documentation system 
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Appendix 16 – BioRad® Bovine Serum Albumin (BSA) micro-assay for Protein 
Quantification 
 
Equipment 
§ Small sterile glass test tubes (12 x 75 mm) (B&M Scientific, Cape Town, South Africa) 
§ Hitachi U-1100 UV/VIS spectrophotometer (Koki CO, Ltd., Tokyo, Japan) 
§ Cuvette (plastic) 
 
Reagents 
§ 1 mg/ml bovine serum albumin (BSA) (Sigma-Aldrich, St. Louis, MO, USA) 
§ Bio-Rad® Protein Assay Dye Reagent Concentrate (Bio-Rad® Laboratories, Munich, 
Germany) 
 
Methodology 
§ Make a 1/10 dilution of BSA (i.e. 0.1 mg/ml) 
§ Prepare 6 linear dilutions of the 0.1 mg/ml BSA (20-70 µl in final volume of 800 µl) 
§ Prepare relevant dilutions of samples and include a blank (negative control) 
§ Add 200 µl Bio-Rad® dye reagent to each tube and vortex; avoid bubbles 
§ Incubate at room temperature for 5 minutes (1 hr max) 
§ Set spectrophotometer (595 nm) and read samples against relevant blank 
 
§ Generate and plot standard curve from BSA concentrations and absorbance 
§ Plot linear trend-line 
§ Extrapolate concentration of samples from the standard curve 
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Appendix 17 PBGD Activity Assay 
 
Equipment  
§ 0.2 µm PTFE filters (B&M Scientific, Cape Town) 
§ Aluminium tube rack 
§ Eppendorf repeater pipette (Merck Millipore, RSA)  
§ Small sterile glass test tubes (12 x 75 mm) (B&M Scientific, Cape Town, South Africa) 
§ Hitachi 650/10S Fluorescence Spectrophotometer (Koki, Co (Ltd), Japan) 
§ Hitachi U-1100 UV/VIS spectrophotometer (Koki CO, Ltd., Tokyo, Japan) 
§ Memmert shaking water incubator (Lab and Scientific, Cape Town) 
§ Plastic cuvettes (4.4 ml) 
  
Reagents 
§ 5N HCl solution 
§ 0.5N HCl solution 
§ 1 mg/ml Uroporphyin I (in 5N HCl) (Frontier Scientific, USA) 
§ 5.5 mM Dithiothreitol (DTT) (Sigma, St Louis, MA USA)  
§ 5 mM PBG (substrate) (Frontier Scientific, USA) 
§ 39 nM PBGD 
Store at 4⁰C 
 
§ Assay Buffer: 0.1M Tris-HCl 
§ Cuvette Buffer: 0.01M Tris-HCl 
 
Methodology 
 
Standard 
§ Pipette 50 µl from 1 mg/ml Uroporphyrin I stock solution and add 4.95 ml of 5N HCl. 
This solution is the working solution and is stable for ± 1 week. Importantly, filter and 
measure absorbance prior to every assay 
§ From the working solution make a 1/100 dilution in 0.5N HCl 
§ Measure the absorbance at 405 nm in the spectrophotometer. Determine the 
concentration of the working solution by the Beer-Lambert Law (A=ɛCl) where ɛ(UroI) = 
541 mM 
§ From the working solution pipette 250 µl into a glass tube and add 6 ml of 5N HCl. This 
is a 1000X standard 
§ Make a serial dilution range from 1000X in 5N HCl. 10, 25, 50, 100, 150, 200, 250 
§ Use the 250 dilution and set the fluorimeter to 1000 (excitation wavelength, 405 nm 
and emission, 595 nm), with slit widths of 6 and 6.5 cm, respectively at a. Sensitivity of 
x1 
§ Plot a graph (linear) using the standards readings to determine activity 
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Assay 
• Set shaking water incubator to 37⁰C 
• Place aluminium tube rack on ice 
• Make up a 1 mg/ml Uroporphyrin I solution in 5N HCl to use as standard; taking care 
to keep sample on ice and in the dark (cover with foil). Work in dim light. 
• Make up the 5.5 mM DTT and 5 mM PBG in Assay Buffer; keep on ice  
• Dilute PBGD (sample) in Assay Buffer 
• Prepare samples of BSA of equivalent concentration as the PBGD to act as a blank 
• Add the following to each cuvette; where possible using an Eppendorf repeater pipette  
o 920 µl   Assay Buffer 
o 10  µl  DTT 
o 20  µl  PBG 
o 50  µl  PBGD 
• Immediately after adding the PBGD vortex, and incubate in shaking water incubator at 
37⁰C in the dark for 20 minutes. 
• Terminate the reaction by adding 100 µl of 5N HCl and vortex briefly 
• Place samples in area of bright light for 20 minutes. 
• Add 1 ml Cuvette Buffer to each sample. 
 
• Measure fluorescence at excitation wavelength of 405 nm and emission wavelength at 
595 nm 
 
 
Note: Ensure (if necessary, by optimization) that all concentrations of PBDG measured fall 
within the linear part of the curve 
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Appendix 18 Kinetic Assay 
 
All equipment and reagents are as detailed in Appendix 17, apart from these mentioned below: 
  
Reagents 
§ 0.5 mM PBG (substrate) 
§ 19.5 pM PBGD 
 
Methodology 
 
Standard  
As detailed in Appendix 17 
 
Assay 
• Make up 0.5 mM PBG in Assay Buffer; keep on ice  
• Add increasing concentrations of PBG to each successive tube over an appropriate 
range at the same concentration of PBDG (19.5 pM) 
• For each concentration of PBG – have a BSA blank 
• Volumes for the highest PBG concentration as follows: (as an example) 
o 760  µl  Assay Buffer 
o 10  µl  DTT 
o 180  µl  PBG 
o 50  µl  PBGD 
 
• Perform Assay as detailed in Appendix 17 
 
 
Note: Kinetic Assay requires - optimization with regards to the PBGD concentration for both 
wild type and mutants in order to ensure that maximal velocity is reached and that the 
concentration of PBGD used is not too great. 
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Appendix 19 – DPM Co-Factor Analysis  From Hart et al. (1988) [78]  
 
Equipment: 
§ SpectraMaxPlus 384 Spectrophotometer, Molecular Devices (Labotec, RSA) 
§ Geiner bio-one 96-well flat bottom microplate (Laboratory & Scientific (Pty) Ltd, CT, 
RSA) 
 
Software 
§ SoftMax Pro Microplate Data Acquisition & Analysis Software, Molecular Devices 
(Labotec, RSA) 
§ GraphPad Prism, Version 6.03 for Windows. (Used Spaghetti graphs – multiple y output 
for single x input) 
 
Reagents 
§ 2M HCl freshly prepared 
§ 2% 4 - (dimethylamino)benzaldehyde (DAB) 
§ 98% formic acid 
§ 0.5 mg/ml PBGD enzyme solution 
 
Methodology 
§ Prepare the modified Ehrlich’s reagent as follows: Dissolve 2% DAB in a 98% formic 
acid/2M HCl solution in the ratio of (7:3 v/v) 
§ Dilute the pure eluted protein (Appendix 13 & 16) to a final concentration of 0.5 mg/ml 
§ Set up the SoftMax Pro software to scan absorbance from 440 nm to 650 nm at 5 nm 
intervals. Apply the auto-calibration settings for every reading. 
§ Add 75 µl of both enzyme and Ehrlich’s reagent into the 96-well microplate. Ensure no 
bubble formation & that the bottom of the well is completely covered to avoid false 
readings. 
§ Include a well containing only Ehrlich’s reagent as a negative blank. 
§ Immediately after adding the Ehrlich’s reagent to samples (note in WT and K98E bright 
pink colour), insert microplate into spectrophotometer to scan. Note these readings as 
time 0 (T0). Set a timer for 20 minutes 
§ Following 20-minute incubation repeats the scan. Note readings as time 20 (T20) 
§ Export readings as text files. Analyse and generate graphs using desired software 
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Appendix 20 – DPM Co-Factor Removal From Hart et al. (1988) [78]  
 
Equipment: 
§ Amicon® Ultra 4 ml centrifugal filters (30 kDa cut-off) (Merck Millipore, South Africa) 
§ Standard (RC) Membrane Dialysis tubing 10mm (25 kDa cut-off) (GIC Scientific, 
Roodepoort, South Africa) 
§ Small sterile glass test tubes (12 x 75 mm) (B&M Scientific, Cape Town, South Africa) 
 
Software 
§ SoftMax Pro Microplate Data Acquisition & Analysis Software, Molecular Devices 
(Labotec, RSA) 
§ GraphPad Prism, Version 6.03 for Windows. (Used Spaghetti graphs – multiple y output 
for single x input) 
 
Reagents 
§ 2 mg/ml DTT 
§ 1.75 mg/ml HMBS purified enzyme 
§ Conc. HCl 
§ 6M Urea solution 
 
§  “Buffer 1”   (pH 7.2) 
o 50 mM NaPO4 
o 0.6 mM EDTA 
o 1 mM DTT 
o 0.1M NaCl 
o 0.1M Urea 
 
§ “Buffer 2”   (pH 7.2) 
o 50 mM NaPO4 
o 0.6 mM EDTA 
o 1 mM DTT 
o 0.1M NaCl 
 
§ “Buffer 3”   (pH 7.4) 
o 50 mM NaPO4 
o 0.6 mM EDTA 
o 0.2 mM DTT 
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Methodology 
§ DTT was added at a concentration of 2 mg/ml to HMBS (1.75 mg/ml) followed by 
concentrated HCl to a final concentration of 1M 
§ Protein will immediately precipitate; cover with foil and leave in the dark for 25 hours at 
RTP. (Solution will turn bright pink as pyrromethane has been cleaved) 
§ Collect protein by centrifugation (20 000 g for 10 minutes) 
§ Resuspended protein in 45 ml of Buffer 1 and added to dialysis tubing & dialysed 
against same buffer for 90 minutes at RTP.  (Stirring required) 
§ Dialysis tube transferred to 5L bottle of Buffer 2 and continues dialysis at 5°C for 24 
hours. Exchange buffer minimum of 3 times (no stirring) 
§ Dialysis exchanged to Buffer 3 for overnight dialysis (with stirring) at 5°C. Exchange 
buffer minimum of 3 times 
• Collect sample from dialysis tubing and keep on ice. 
• Concentrate protein using Amicon® filter tubes  
o Important – exchange samples in order to prevent protein precipitation. Then 
concentrate final sample volume 
• Determine protein concentration (Appendix 16) 
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Appendix 21 – ‘Apo’- Enzyme Reconstitution Assay   
 
All equipment and reagents are as detailed in Appendix 17, apart from these mentioned below: 
  
Reagents 
§ 0.5 mM PBG (substrate) (1.22 mg/ml) 
§ 0.5 mM DPM cofactor (1.69 mg/2ml) 
§ 50% MeOH 
§ 1M imidazole solution 
§ 0.5 mg/ml PBGD enzyme solution 
 
Methodology 
 
Standard  
As detailed in Appendix 17. 
 
Assay 
§ Make up 0.5 mM PBG in Assay Buffer; keep on ice  
§ Make up 0.5 mM DPM cofactor in 50% Meth-OH and 50% imidazole solution; keep on 
ice 
§ Volumes for the assay as follows: (as an example) 
o 920 µl Assay Buffer 
o 10 µl DTT 
o 20 µl PBG (or DPM) 
o 50 µl PBGD 
§ Perform Assay as detailed in Appendix 17 
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Appendix 22 – PD10- Column Buffer Exchange   
 
Equipment: 
§ PD-10 Desalting Columns (GE South Africa Pty Ltd, Midrand, South Africa) 
§ Small sterile glass test tubes (12 x 75 mm) (B&M Scientific, Cape Town, South Africa) 
 
Reagents: 
§ 0.2% sodium azide solution 
§ CD Buffer (Appendix 23) 
§ 2.5 ml Purified PBGD enzyme 
 
Methodology: 
§ Decant storage solution in PD 10 column 
§ Equilibrate column with minimum of 25 ml of desired final buffer (i.e. CD Buffer) 
 
§ Aliquot 2.5 ml of purified protein. 
o In case of mutants with smaller amount yield, aliquot as much of protein as 
possible and make-up to a final volume of 2.5 ml with equilibration buffer 
(Appendix 13) 
 
§ Add the 2.5 ml of protein and allow to flow through 
o Wait until there is no further flow through  
 
§ Measure 3 ml of CD buffer & add to column in order to elute protein 
§ Store at 4°C 
§ Determine protein concentration (Appendix 16) 
 
 
  
   115 
 
Appendix 23 – Circular Dichroism (Far UV  &  Near UV ) from Bustad et al. (2013)[96]   
 
Equipment: 
§ 106 QS, 0.5 mm P1X Cuvette (200 µl) (CAF, Stellenbosch University) 
§ Chirascan Plus CD Spectrophotometer (Applied Photophysics Limited, United 
Kingdom) 
§ PCS.3 Single Cell Peltier Temperature Controller (Applied Photophysics Limited, 
United Kingdom)  
§ Soft Kleenex Tissues 
 
Software: 
§ Chirascan Windows™ Software (Applied Photophysics Limited, United Kingdom) 
§ Pro-Data Viewer Version 4.0 (Applied Photophysics Limited, United Kingdom) 
 
Reagents: 
§ CD Buffer  (pH 8.2) 
o 10 mM KPO4  
o 100 mM (NH4)2 SO4 
§ Distilled H2O 
§ Acetone 
§ Conc. HCl 
 
Methodology 
§ Start-up CD machine, and allow 15 seconds before switching on the lamp 
§ Start-up and set the temperature controller to 20°C 
§ Open the nitrogen gas valve and ensure flow-meter gas inlet as follows: 
o sealed lamp housing: requiring 1 l/min 
o sealed monochromator: requiring 3 l/min (or 1 l/min when working > 200 nm) 
o sealed light path within the sample chamber:  requiring 1 l/min (or zero purge 
> 200 nm)  
 
§ Start up the lamp and allow minimum of 15 minutes for lamp to equilibrate 
§ Dilute protein samples to required concentration using CD Buffer (7 µM) and keep on 
ice 
§ Wash cuvette with acetone to remove and residual sample or contaminants. 
§ Wash cuvette with distilled H2O a minimum of 3 times 
§ Rinse cuvette with CD buffer multiple times 
§ Start the Chirascan software program  
o Set the wavelength range to start at 300 nm and end at 190 nm. 
o Set machine to read ‘millidegrees’ and not absorbance 
o Select ‘adaptive sampling’ 
o Select ‘spectrum’ 
§ Start Pro Data Viewer 
o Preferences > ‘Go online’ 
o Set the folder of choice as the working directory 
 
§ Aliquot CD buffer into cuvette and read a scan for the wavelength.  (Blank) 
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Note: if the blank reading shows peaks, specifically around 222 and 190 nm – there is possible 
*residual sample left in the cuvette. Soak cuvette with acid for 2-5 minutes and repeat cuvette 
washing. 
 
*Should also be visible if y-axis is changes to absorbance – value should not exceed 2.0 A. 
 
 
§ Aliquot sample and scan for far-UV range at 25°C. 
§ Rinse cuvette & repeat. (ensure concentration is uniform – check absorbance levels) 
 
Note: more information on the specifications of the Chirascan plus, accessories and manuals 
can be found on the Applied Photophysics website [https://www.photophysics.com] as well as 
on the Central Analytical Facility website [http://academic.sun.ac.za/saf/] 
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Appendix 24 – CD Protein Thermal Assay  from Bustad et al. (2013)[96] 
 
Similar set up as Appendix 23 
 
Methodology: 
§ Set the wavelength to measure at 222 nm 
 
§ Set the temperature (under Advanced setting) 
§ Allow the temperature range from 20 - 90°C 
o Set the interval in 5°C 
§ Following temperature set machine to return to starting temperature (20°C) 
 
§ Enable ‘stepped ramping’ 
o Rationale – the temperature monitor of the sample holder heats up faster than 
the solution (i.e. true temperature measured by thermometer) hence allowing 
for stepped ramping ensures the true sample temperature is as close as 
possible to the sample holder 
o Allow setting time of 300 seconds maximum.  
§ Before attempting the temperature scan – perform a quick far UV scan to ensure protein 
is correct concentration as well as checking for contaminants (strange signal etc.) 
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Appendix 25 – Native PAGE Courtesy of Ms. Helene J. Bustad (Norway)  
 
Equipment: 
§ Bio-Rad® Gel Casting Kit (Courtesy of Department of Surgery) 
§ PS1500 DC Power Supply (Hoefer Scientific Instruments, San Francisco, USA) 
§ UVItec gel documentation system (UVItec Limited, Cambridge, UK) 
§ K65HM high-density synthetic paper (Whitehead Scientific, South Africa) 
 
Reagents: 
§ Running gel buffer: 1.5M Tris-­‐HCl, pH 8.8 
§ Stacking gel buffer: 0.5M Tris-­‐HCl, pH 6.8 
 
§ 10 % Running gel 
o 10 ml A-Bis-A (30% acrylamide, 0,8% bis-acrylamide) 
o 12 ml H2O 
o 7.5 ml Running Buffer 
o 20 µl TEMED 
o 150 µl  10% ammonium persulphate (fresh) 
 
§  4 % Stacking gel 
o 1.33 ml A-Bis-A 
o 6.1 ml H2O 
o 2.5 ml Stacking buffer 
o 10 µl TEMED 
o 50 µl 10% ammonium persulphate (fresh) 
 
§ Running the gel 
o Tank buffer: 0.025M Tris-­‐HCl, 0.192M Glycine, pH 8.3 
o Sample buffer (5 mL, w/o denaturing agents) (store in aliquots at −20 °C): 
§ 125 mM Tris/HCl (0.1514 g) 
§ 2.5 ml Stacking gel buffer 
§ 10 % v/v glycerol  (1.15 mL of 87 % glycerol) 
§ Very little (0.002 %) Bromphenol Blue A few grains 
§ H2O to 5 mL 
§ Do not boil samples (will cause denaturation) 
§ Load between 5 – 10 µg of protein 
§ Run gel at 150 V and 20 mA (approximately 45 minutes) 
§ Stain (Appendix 15) 
§ Visualize using UVItec gel documentation system 
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